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Individuals with metabolic syndrome (n = 15) were fed two hypocaloric diets, ~500 kcal
below energy requirements, of individually prepared foods for 21 days. The diets
consisted of a low-carbohydrate diet (LCD) (% carbohydrate:fat:protein = 7:74:20) and a
low-fat diet (LFD) (55:28:20) reflective of the current US dietary recommendations. The
LCD diet resulted in a net weekly intake of 2.69 g of arachidonic acid (ARA) in
comparison to the 1.27 g/wk consumed during the LFD. The LCD significantly increased
plasma ARA and decreased dihomo-gamma-linolenic acid (DGLA) in all three
circulating lipid fractions as well as buccal cells in comparison to the LFD. Correlational
analysis of plasma lipids with HOMA2 scores showed plasma ARA to be positively
associated with insulin sensitivity in all three lipoprotein fractions during both diet
phases. Total buccal cell ARA did not correlate to measures of insulin sensitivity in either
diet phase, but DGLA was negatively correlated to insulin sensitivity during the LCD.
The highly significant and consistent increase in circulating ARA after feeding a lowcarbohydrate diet could be a result of multiple factors including better preservation of the
existing ARA pool, increased dietary intake, greater endogenous synthesis and greater
release into the circulation from adipose triglyceride stores. Given the importance of
ARA in cellular membranes as it relates to insulin sensitivity, these results indicate that a
low-carbohydrate diet promotes a favorable circulating and membrane fatty acid
composition.
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Chapter 1: Introduction

Overview

In the last 50 years the United States has seen a dramatic rise in obesity. In the early
1960’s the prevalence of obesity among the US population was ~10%, however by 2010
this percentage increased up to ~36% indicating that greater than one-third of the US
adult population had become obese (44-46). Obesity is often viewed from the
perspective of energy imbalance manifesting when intake of calories exceeds the amount
of calories being expended. But calories are not treated equally metabolically. The level
of carbohydrate consumption can strongly direct processes such as oxidative disposal, de
novo lipogenesis and adipose storage. Therefore the emphasis should be placed on the
macronutrient composition of the diet (as opposed to energy balance) and how the ratio
of carbohydrate to fat drives factors in the etiology of obesity and insulin resistance.

The greatest increase in the obesity epidemic occurred during the period of 1976 to 1999.
Tracking of patterns and trends in food portion sizes during this time interval indicated a
dramatic increase in food portion sizes, particularly in meals consumed at home and in
fast food restaurants (115). The growth in portion sizes increased overall caloric intake
from 1791 kcal/d in the late 1970’s to 1985 kcal/d in the mid 1990’s with the most
dramatic portion of this increase occurring during the early to mid-90’s (115). The
increase in calories was derived from carbohydrate with little change in protein and fat
(183). This net increase of 194 kcal/d, principally from carbohydrate, equates to an
increase of ~20 lbs of body weight a year. During this same time interval there was also a
dramatic increase in the consumption of high fructose corn syrup (HFCS) and during the
early to mid-90’s was the greatest rise in total sweetener consumption (refined sugar,
HFCS and others) (65). Chronic hypercaloric consumption does not simply lead to
increases in body mass, but also leads to inflammation, metabolic and cardiovascular
disorders. Obese individuals can display elevated systolic and diastolic blood pressure,
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elevated triglycerides, insulin, HOMA-IR, CRP and MCP-1 (87, 166, 169). As the
obesity epidemic spread and a growing number of metabolic and cardiovascular risk
factors started to become associated with it, a new classification known as Metabolic
Syndrome (MetS) was developed. MetS is a cluster of metabolic and cardiovascular risk
factors that can lead to cardiovascular disease and diabetes (62). These risk factors are
specifically defined as abdominal obesity, hypertension, dyslipidemia and hyperglycemia
which relate to the physiological measures of waist circumference, blood pressure,
triglycerides, HDL-C and fasting plasma glucose, which are all linked with dietary
carbohydrate intake ((173)). Data complied from NHANES indicated that 56% of US
adults had a waist circumference that would qualify them for MetS in 2009-2010 (127).
The underlying causes of MetS are thought to be abdominal obesity and insulin resistance
(62). Proper treatment of MetS to reverse the health risks and mortality associated with it
(including obesity) require interventions aimed at reducing excess body mass and
improving insulin sensitivity, which should include attention toward an appropriate level
of dietary carbohydrate.

In comparison to a low-fat, high carbohydrate diet, a low carbohydrate, high fat diet leads
to greater decreases in body weight, fasting glucose, insulin, HOMA-IR, triglycerides and
improves HDL-C (174). A low carbohydrate diet also leads to greater improvements in
circulating markers of inflammation such as TNF-alpha, IL-8, MCP-1, I-CAM and ESelectin (49). Although a low fat, high carbohydrate diet can decrease body weight and
improve some markers of inflammation, the overall benefits of a low carbohydrate diet in
regards to the risk factors associated with MetS such as abdominal obesity, triglycerides,
HDL-C, plasma glucose, insulin sensitivity and inflammation are greater. Although some
of the mechanisms behind the greater weight loss with a low carbohydrate diet are
understood (102), how this diet improves insulin sensitivity, one of the underlying
causes of MetS, has been less studied.

Although the insulin signaling cascade has been well characterized, insulin resistance is a
multifaceted and complex phenomenon. Much of the research has focused on the protein
components of the insulin signaling cascade (172), however there is evidence that the
2

lipid composition of skeletal muscle membranes are highly associated with measures of
insulin sensitivity (13, 121). The purpose of this dissertation project is to determine the
affect of dietary macronutrient composition on cellular membrane composition, whole
body insulin sensitivity and to determine the relationship between cellular lipids and
insulin sensitivity.
Study Design

Individuals with MetS (n = 15) underwent 5 months of controlled hypocaloric feeding
subdivided into seven, 3-wk diet phases. Subjects started with a guided free-living low
carbohydrate phase prior to controlled feeding. Participants were then fed individually
catered prepared meals containing progressively increasing quantities of CHO (47g, 82g,
131g, 179g, 250g and 344g of carbohydrate). Blood samples were collected following an
overnight (10-12 h) fast at the end of each 3-wk diet phase.

Aims
Aim 1. To demonstrate that variations in carbohydrate intake will alter the composition
of plasma lipids. My working hypothesis is that lower carbohydrate intake will increase
polyunsaturated fats (PUFA), specifically arachidonate and DHA, decrease saturated fats
(SFA), specifically laurate, myristate and palmitate, and decrease 16:1n7 which is
associated with de novo lipogenesis (DNL), relative to a standard American diet.
Novelty. Although there were 7 diet phases, this dissertation will only focus on the diet
phases with the lowest and highest carbohydrate intake. The controlled feeding allows
for analysis of the fatty acid composition of the diet and to correlate these changes to
those found in the serum across different quantities of carbohydrate feeding.
Aim 2. To demonstrate that the macronutrient composition of the diet will change the
lipid composition of buccal cell membranes. Buccal cells can be obtained non-invasively
and have demonstrated changes in lipid composition with changes in dietary fat intake
(106).
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Working Hypothesis #1: Fatty Acid Composition. A low carbohydrate diet will
increase arachidonic acid (ARA), a fatty acid highly associated with insulin sensitivity
and decrease di-homo-gamma linolenic acid (DGLA), an arachidonic acid precursor
associated with insulin resistance.
Working Hypothesis #2: Blood vs Membrane Composition. The change in buccal cell
membrane composition of arachidonic acid will mimic the change in plasma arachidonic
acid.
Novelty. Buccal plasma membrane composition in individuals with MetS has never been
assessed, nor the effects of carbohydrate intake on buccal membrane composition.
Aim 3. To observe correlations between changes in the lipid composition of buccal cell
plasma membranes and whole body insulin sensitivity.
Working Hypothesis: The low carbohydrate intake will improve whole body insulin
sensitivity. This change will be positively correlated to arachidonic acid and negatively
correlated to DGLA as has been previously observed in skeletal muscle.
Novelty. Insulin sensitivity in individuals with MetS has not been previously correlated
to the fatty acids of buccal cells, nor has the effect of carbohydrate intake on variations in
the relationships between buccal cell fatty acids insulin sensitivity.
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Chapter 2: Review of Literature

Introduction

Although obesity and metabolic syndrome have clearly characterized definitions, the
mechanisms behind these metabolic disorders are less clear. Obesity is often explained as
a mechanism behind insulin resistance and MetS is believed to be caused by abdominal
obesity and insulin resistance. However, evidence indicates that obesity, insulin
resistance, changes in circulating FFA and TG and even blood pressure (the factors
associated with MetS) are all downstream effects of chronic hypercaloric intake. The
importance of the macronutrient composition of the diet to the contribution of obesity and
other metabolic dysfunctions as well as to the reversal of these metabolic alterations will
be investigated below. Some of the known mechanisms of insulin resistance will be
delineated and related back to the metabolic alterations induced by overfeeding. Many of
these mechanisms are related to the proteins involved in the insulin signaling cascade, but
there is evidence that cellular lipids may also impact insulin sensitivity. The concepts of
cell membrane composition and organization and their relationship to insulin sensitivity
will also be discussed as well as the efficacy of leukocytes as a model system for the
study of insulin resistance at the level of the cell. A summary of these findings will be
used to explain the rationale behind the paradigm of this project.

Definition of Obesity and Metabolic Syndrome

Obesity is defined as a body mass index of 30 or greater (21). MetS is defined by a
cluster of clinical risk factors that predispose individuals to cardiovascular disease
(CVD), type II diabetes mellitus (T2DM) and all-cause mortality (61, 127). These risk
factors are commonly known as abdominal obesity, hypertension, dyslipidemia and
hyperglycemia which are clinically defined as elevated waist circumference (≥102 cm for
men and ≥88 cm for women), elevated blood pressure (systolic BP ≥130 mm Hg,
5

diastolic BP ≥85 mm Hg), elevated triglycerides (TG ≥ 150 mg/dL), low HDL-C (<40
mg/dL for men, <50 mg/dL for women) and elevated fasting plasma glucose (≥110
mg/dL) (61). The cause of both of these metabolic disorders is hypercaloric intake. The
metabolic perturbations associated with hypercaloric intake are dependent on the
macronutrient composition of the diet. Evidence to support the claim that hypercaloric
intake precedes obesity, MetS, insulin resistance and the associated pro-inflammatory
state comes from investigations of short-term overfeeding.
Overfeeding/Hypercaloric Intake

Dissociation of Obesity and Insulin Resistance
In the US, increased insulin resistance is associated with excess body mass, typically the
result of chronic hypercaloric intake (59).Two studies observed the effects of a mixed
hypercaloric diet with an increase in body mass index within the normal range (BMI
<25). Both studies demonstrated increases in fasting insulin concentrations and an
increase in the HOMA-IR (implying a decrease in insulin sensitivity)(14, 41).
Furthermore during an OGTT there was an increase in the AUC of insulin explained by a
decrease in the rate of insulin clearance and an increase in insulin secretion (14, 41).
Similar increases in the AUC of insulin as a result of a decrease in insulin clearance and
an increase in insulin secretion were observed after a test meal (260 kcal, 62% CHO,
32% FAT and 6% PRO) (41). Although these studies did observe statistically significant
increases in body weight, these changes were within a normal BMI demonstrating the
dissociation of decreased insulin sensitivity with obesity.
Dissociation of Inflammation and Insulin Resistance
Insulin resistance can also be dissociated from inflammation. Individuals fed a mixed
hypercaloric diet for 3 days showed a weight gain of ~2.7 kg (< 1.0 kg/m2) and
demonstrated increased fasting glucose and insulin with decreased insulin sensitivity (by
hyperinsulinemic-euglycemic clamp) (160). Although a statistically significant increase
in CRP was observed the post-hypercaloric feeding values were still within the normal
clinical range. MCP-1 showed a statistically significant increase, but there were no
changes in sICAM-1, the number of circulating leukocytes, leukocyte activation markers,
6

the number of subcutaneous adipose tissue macrophages or the M1/M2 macrophage ratio
in subcutaneous adipose tissue. These results indicate that there were decreases in insulin
sensitivity without significant increases in inflammation or weight gain. Together these
studies demonstrate the dissociation of obesity and inflammation from increases in
insulin resistance.
Macronutrient Composition and Metabolic Complications
The preceding paragraphs demonstrated that hypercaloric intake, prior to the onset of
obesity and inflammation, begins the process of insulin resistance. However, it is the
macronutrient composition of the hypercaloric diet that dictates the metabolic
disturbances attributed to short-term overfeeding. Mixed hypercaloric diets by majority
tend to demonstrate increases in fasting insulin and decreases in insulin sensitivity (14,
41, 120, 160). Hypercaloric high carbohydrate diets demonstrate increases in fasting
insulin and triglycerides with decreases in serum FFA(4, 26, 36, 73, 154, 180).
Hypercaloric high fat diets tend to show no change in fasting glucose, or fasting insulin, a
decrease in serum FFA and decreases in triglycerides (4, 17, 36, 73, 154). Hypercaloric
diets only show significant increases in body weight with interventions lasting greater
than 1 week, after which they all demonstrate increases in body weight (4, 14, 26, 36, 41,
73). The metabolic perturbations associated with each diet are the physiological
outcomes of the metabolic machinery attempting to adapt to hypercaloric intake. The
etiology of the underlying mechanisms can explain the observed perturbations when
CHO or fat are overfed.

Management of Excess CHO and Fat
Humans typically store approximately 500g (2000 kcal) of CHO as glycogen distributed
in a 4:1 ratio between muscle and the liver (104). In contrast adipose tissue and skeletal
muscle can store greater than 6 kg (60,000 kcal) of triglycerides, the storage form of fat
(104). The capacity of the human body to store fat is much greater than its ability to store
CHO. Excess fat can be managed through storage or oxidation, but limitations in CHO
storage requires greater metabolic flexibility to manage excess CHO intake. Possible
pathways to manage excess CHO are storage as glycogen, oxidation, conversion to fatty
7

acids (de novo lipogenesis, DNL) and fecal excretion. These pathways are
interdependent.

Macronutrient Metabolism
CHO and fat overfeeding have very different effects on macronutrient oxidation and
energy expenditure. Hypercaloric high CHO diets (HHCD) show increased CHO
oxidation, decreased fat oxidation and an overall increase in total energy expenditure
(TEE) (1, 3, 26, 73, 105, 141). Hypercaloric high fat diets (HHFD) tend to either not
alter fat oxidation or increase it, while not changing CHO oxidation or TEE (73, 105,
141). These differences in energy metabolism occur due to the limitations of CHO
storage. At the onset of a HHCD, disposal of excess CHO is dispersed between increased
CHO oxidation and storage, with glucose carbons stored as either glycogen or fat through
DNL. The greatest increase in glycogen storage takes place at the onset of the HHCD and
although there are increases in both whole body and hepatic DNL, there is no net DNL
(fat synthesis > fat oxidation) at this early stage (1, 3). Similarly although CHO oxidation
is significantly increased, the increase in CHO oxidation is not yet enough to significantly
increase REE. However, by the fourth day of an HHCD the RQ > 1.00 indicative of net
DNL, CHO oxidation has increased to the point of significantly increasing REE and
glycogen stores have stabilized, having increased to a total of ~800-1,000g (1, 3).
Beyond this point CHO can no longer be stored as glycogen leading to either greater
increases in CHO storage as fat through DNL or oxidation. Fecal excretion was assessed
21 days after either an HHCD or HHFD and showed that the HHCD in comparison to the
HHFD had a 44% increase in dry weight, a 30% increase in loss of energy and greater
losses in CHO and PRO (91). Since fecal excretions were only measured on a single day
during the hypercaloric diets, the time course of these changes cannot be discerned. This
exact time course of events may not be true for all HHCD and likely depends on the
quantity of excess calories and the percentage of CHO in diet. However it does delineate
that excess CHO are first stored as glycogen prior to major increases in both CHO
oxidation and net DNL.
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De Novo Lipogenesis
De novo lipogenesis is the synthesis of fatty acids from glucose derived carbons. Glucose
is converted to acetate via glycolysis and subsequently synthesized into fatty acids via
fatty acid synthase. Under eucaloric conditions whether high fat or high CHO, there is no
net DNL and the absolute quantity of lipid produced was < 10g/dy (68, 76, 77).
Overfeeding shows dichotomous results. Five days of overfeeding fat (~1523 kcal or
50% EE extra) had no effect on hepatic DNL, but CHO overfeeding (~1827 kcal, 50%
EE extra ) increased hepatic DNL to a rate of < 5g/d with no net DNL (68, 141). In
contrast, CHO overfeeding for 7 days (incremental increases in total kcal from 3600 to
5000) increased net whole body DNL producing 142 g/d (3). Another study which
overfed CHO for 4 days (2.5x TEE total) demonstrated up to 170g/d of DNL (1). A third
study which overfed CHO (~1816 kcal extra in lean subjects) for 4 days showed a
significant increase in net DNL of ~28 g/d (109). The discrepancies in the quantity of
DNL in the overfeeding literature likely arise from the percentage of CHO in the diet and
the composition of CHO. Studies which observed an increase in net DNL, derived 75%
or more of total calories from CHO, while the single study which did not show net DNL
fed 70% of calories from CHO. The ratio of simple:complex CHO was not disclosed in
most of these studies but simple CHO have a much stronger affect on DNL than complex
CHO (76, 78). Although the quantity of DNL with CHO overfeeding is currently
irreconcilable, its’ increase is still important as it indicates an important shift in
metabolism.

Fate of Glucose Carbons
DNL indicates the conversion of glucose to fatty acids, but under normal dietary
conditions in healthy adults, the majority of glucose converted to lipid is in the form of
glycerol. Glycerol is synthesized from glucose through entry into the glycolytic pathway
until dihydroxyacetone phosphate (DHAP) is generated. DHAP is converted to glycerol
by the subsequent actions of glycerol-3-phosphate dehydrogenase and glycerol-3phosphatase. This process is referred to as the Kennedy pathway. Evidence that the
majority of glucose carbons are converted to glycerol and not fatty acids under normal
conditions has been demonstrated in vitro in adipose tissue. In vitro cultures of human
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abdominal adipose tissue biopsied from healthy or non-diabetic subjects showed between
72-99% of labeled glucose was incorporated into glycerol and only about 1-28% was
converted to fatty acids (53, 57, 60, 145, 146). In vivo evidence that glycerol is the
dominant lipid generated by glucose is derived from studies that infuse labeled 14Cglucose. In lean healthy individuals on a normal diet, greater than 90% of labeled
glucose carbons were located in the glycerol moiety of isolated VLDL-TG with less than
6% in the VLDL-TGFA (8, 10). However, consumption of a HHCD alters the allocation
of glucose carbons between glycerol and fatty acids. Two days of an HHCD decreased
the appearance of labeled glucose carbons in VLDL-glycerol to ~28% and increased the
quantity of labeled glucose carbons to ~72% in VLDL-TGFA (8). A potential
mechanism for this switch between glycerol and fatty acid production might be the
increase in plasma insulin associated with HHCD. The promoter region of the fatty acid
synthase gene has an insulin response element (177). Adipose tissue segments from
human biopsies incubated with varying concentrations of insulin and radiolabeled
glucose demonstrated that the proportion of labeled glucose carbons increased in the fatty
acid fraction (60). Notably, the increase in labeled glucose carbons in fatty acids
occurred at physiological levels of insulin (60). Even if an HHCD does not increase
DNL above lipid oxidation, it still has an important physiological role in explaining the
modifications to lipid metabolism observed in obesity and MetS.

Effects of DNL on Serum Lipid Composition
Induction of DNL by HHCD plays an important role in regulating the plasma
concentrations of FFA and TG as well as the lipid composition of serum lipids.
Consumption of an HHCD for 4 days decreased total plasma fatty acids, but increased the
concentrations of palmitate and palmitoleate and decreased the concentrations of oleate
and linoleate (2). The decrease in total plasma FFA can be explained by a decrease in the
net transport rate of FFA (lipolysis) while the clearance rate is increased (9). These
changes in FFA cycling are observed in both HHCD and isocaloric high CHO diets (9).
The increased rate of clearance may be due to an increased rate of re-esterification of
plasma lipids. Hypercaloric intake of ~2500 kcal showed greater rates of re-esterification
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than ~500 kcal of hypercaloric intake (67). It is plausible that the increased rate of reesterification that contributes to decreased plasma FFA may also contribute to changes in
plasma TG.

After 4 days of a HHCD total VLDL-TGFA increased nearly 10-fold and although all
VLDL-TGFA increased, palmitate and palmitoleate increased to the greatest extent (12
and 20-fold respectively) (2). The increase in VLDL-TGFA was caused by an increase in
the secretion rate of both de novo VLDL-TGFA and preformed VLDL-TGFA (those
formed from sources other than DNL such as from plasma FFA) (2). Preformed VLDLTGFA increased ~2 fold (212 ± 52 to 566 ± 157 μmol/kg/d) but de novo VLDL-TGFA
increased ~45-fold (3.2 ±1.1 to 150 ± 56 μmol/kg/d) (1). Therefore the increase in DNL
on an HHCD dramatically increased the proportion of fatty acids produced by DNL in the
blood indicating that de novo synthesis plays a controlling factor in serum lipid
composition. DNL predominantly generates palmitate and through subsequent enzymatic
actions of desaturation and elongation can generate palmitoleate, stearate and oleate (2).
The incorporation of fatty acids into triglycerides is dependent upon activation of the
fatty acid by the addition of acetyl-CoA (as demonstrated in adipose tissue) (53, 145).
Palmitate, stearate and oleate show the greatest activation rates for incorporation into TG
(palmitoleate was not assessed) (53, 145). A combination of increased de novo
production and their greater propensity for activation and incorporation into triglycerides
explains why these fatty acids along with palmitoleate and linoleate comprise greater than
97% of VLDL-TGFA (2).

The shift in glucose carbons from producing glycerol to fatty acids, while total
triglycerides are increasing implies another source of glycerol production other than
glucose. Glyceroneogenesis is the production of glycerol from non-carbohydrate sources.
Although evidence for the effects of CHO on glyceroneogenesis are mixed, there are
indications that a HHCD may increase glyceroneogenesis (118). As previously
mentioned a HHCD induced an increase in the PRO content of fecal material, however
nitrogen balance was retained by a decrease in urinary nitrogen excretion (91). Other
investigations of HHCD also showed a decrease in urinary nitrogen excretion and BUN
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(3, 179). Furthermore HHCD has been shown to increase the plasma concentrations of
alanine, leucine, isoleucine, and valine while decreasing serine, threonine and asparagine,
which with the exception of leucine, are all gluconeogenic amino acids (179). While the
concentrations of amino acids with ketogenic potential such as lysine, tyrosine and
phenylalanine showed no change in their concentrations (179). Given that the amino
acids with the greatest change in concentration are gluconeogenic non-carbohydrate
sources of carbon for glyceroneogenesis, there is a possibility that this alternate pathway
to glycerol production contributes to the increase in serum triglycerides. In summary an
HHCD increases DNL, decreases FFA, increases VLDL-TGFA and can modify the lipid
composition of serum fatty acids both free and bound.

Changes in Metabolism Result in Altered Serum Lipids
Overfeeding models demonstrate the potential influence that diet has on serum lipid
concentrations and composition. However, investigations of obesity and MetS have the
potential to validate the precision with which the model fits the actual data. Obese
individuals compared to healthy controls show increases in 16:0 and 16:1n7 in the TG
fraction, 16:0 and 20:4n6 in the CE fraction and 18:0 in the PL fraction with 20:3n6 and
20:4n6 also tending to show increases in the PL fraction. In individuals with MetS in
comparison to healthy controls have increased 16:1n7 and 20:3n6 with decreased 18:2n6
in the PL fraction, increased 16:1n7 and 18:3n6 in the CE fraction and potentially
increases in 16:0, 16:1n7, 18:2n6 and 18:1n9 in the TG fraction, although not enough
data was accumulated. Individuals with MetS in comparison to obese individuals have
increased 16:1n7 and decreased 18:2n6 in the PL fraction, increased 16:1n7 in the CE
fraction with no differences in the TG fraction, but again not enough data was
accumulated on the TG fraction. These data on obesity and metabolic syndrome indicate
that there are significant changes in lipid composition that mirror the model of
overfeeding studies lending credence to the idea that hypercaloric intake can influence
lipid composition and plays a role in metabolic alterations present in obesity and MetS.
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Summary
In summary, the macronutrient composition of the diet is a major determinant in the
progression towards insulin resistance. Short-term overfeeding studies indicate that diets
high in carbohydrate lead to the onset of insulin resistance prior to significant weight gain
that would classify an individual as obese. Therefore diets high in carbohydrate lead to
signs of insulin resistance prior to the onset of other factors commonly associated with
the progression towards MetS such as obesity and inflammation. Furthermore,
modifications to lipid and CHO metabolism during HHCD demonstrate effects on serum
lipid composition which mirror changes observed in individuals with obesity and MetS.

Eucaloric/Hypocaloric Intake

The Macronutrient Composition of Hypocaloric Diets Affects Metabolic Parameters
The combination of caloric excess and a high percentage of CHO lead to greater
metabolic perturbations and signs of dysfunction than a diet with a high percentage of fat
and similar caloric excess. Similarly, with hypocaloric diets, low carbohydrate, high fat
diets (LCD) show greater improvements in metabolic parameters than low fat, high
carbohydrate diets (LFD). Subjects with atherogenic dyslipidemia placed on either a
hypocaloric LCD or LFD for 12 weeks showed decreases in total body mass, BMI, fat
mass, percent body fat, abdominal fat, fasting insulin, HOMA and leptin, but only the
LCD decreased fasting glucose (12%) (174). In comparison to the LFD, the LCD
showed greater decreases in body mass (2x LFD), BMI, fat mass, abdominal fat, insulin
(-49 v -17%), HOMA (-55 v -18%) and leptin (-42 v -18%) (174). LCD also shows
greater improvements in triglycerides (-51 v -19%), HDL-C (+13 v -1%) and the
ApoB/Apo A-1 ratio (-16 v +8%) (174). Regardless of a 3x greater intake of SFA on the
LCD there was a greater decrease in TG-SFA on the LCD (-57 v -24%) (174). The LCD
in contrast to the LFD showed a 31% decrease in palmitoleic acid which can be used as a
marker of DNL due to its low concentration in both the diet and blood (2, 174). The
mean LDL particle size was also increased promoting the less atherogenic pattern A LDL
phenotype (174). An improved LDL phenotype has been commonly observed with diets
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high in fat (38, 89). Both diets led to similar decreases in C- reactive protein (-23%),
VEGF (-21%), P-Selectin (-21%), and V-CAM (-6%), but the LCD showed greater
decreases in TNF-α (-32% v -12%), IL-8 (-33 v -4%), MCP-1 (-24 v -5%), E-Selectin (34 v -14%) and I-CAM (-17 v -3%) (49). Overall a hypocaloric LCD improves body
mass, body composition, glycaemia, plasma lipids and inflammation to a greater extent
than a hypocaloric LFD.

Effects of Dietary Lipids on Serum Lipid Composition
There is not a direct relationship between fatty acid consumption and its concentration in
the blood. Saturated fatty acids (SFA) are a prime example. LCD with 2-3x the dietary
intake of SFA as comparative standard diets and LFDs respectively showed decreased
SFA in the TG and CE fractions of serum lipids (48, 49). In contrast the n3
polyunsaturated fatty acids (PUFA), EPA and DHA, show increased plasma
concentrations with increased dietary consumption. A eucaloric LCD enriched in MUFA
and n3 PUFA demonstrated increased EPA and DHA in both the phospholipid and
cholesterol ester fractions of serum lipids (48). Supplementation with EPA and DHA
increases these PUFA in blood lipids (19, 34, 86, 161, 182). The effect of increased
arachidonic acid (ARA) in the diet is not as straightforward as the n3 PUFA.
Supplementation with ARA increases its concentration in the phospholipid and
triglyceride fractions of blood lipids (56, 84, 90, 161). In two eucaloric LCD, one
enriched in unsaturated fats (UFA) and other enriched in saturated fats with equal
amounts of ARA in the diet, ARA increased in the TG, PL and CE fractions of blood
lipids in the SFA diet, but showed no changes during the UFA diet (48). In addition, the
UFA enriched diet showed decreased DGLA in the PL and CE fractions with an increase
in DGLA in the TG fraction (48). Similar observations have been made with EPA and
DHA supplementation, where concentrations of ARA in blood lipids are usually
unaltered but ARA precursors such as DGLA and LA can show decreases in the PL
fraction (19, 34, 86, 161, 182). These studies indicate that changes in ARA in blood
lipids depends on the consumption of other lipids in the diet.
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Consistent Changes in Serum Lipids Observed with a Hypocaloric LCD
In a hypocaloric LCD model there appears to be consistent changes in serum lipids. ARA
increases while palmitate and myristate decrease resulting in decreased SFA and
increased PUFA in the PL and CE fractions (49, 129, 174). The increase in AA has been
attributed to a decrease in lipid peroxidation as demonstrated by a decrease in urinary 8iso PGF2α (48). Animal models utilizing ketogenic diets show a reduced production of
ROS (83, 88, 157). Another observed change on a LCD is a decrease in 16:1n7 in all
three serum lipid fractions, likely reflecting decreased DNL (49, 174).

Mechanism of Arachidonate Preservation in a Low Carbohydrate Diet
As previously mentioned the increase in ARA is facilitated by a decrease in its oxidative
degradation. Two potential pathways exist which can mediate the reduction in reactive
oxygen species (ROS) production. The first is the Nrf2 pathway. Nrf2 is sequestered in
the cytosol by Keap-1 (82). Keap-1 can be stimulated to release Nrf2 by oxidation of
Cys151 and phosphorylation of Ser40 by PKC (116). Once Nrf2 is released, it
translocates to the nucleus where it can bind the antioxidant response element (ARE).
The ARE is a promoter for at least 2 endogenous antioxidants: the GCL which is
responsible for GSH synthesis and NQO1 which regulates ubiquinones (111, 170, 171,
181). In rats fed ketogenic diets Nrf2 nuclear translocation was increased as well as the
activity of NQO1 and GCL and GSH concentrations (83, 108). The second pathway is via
FOXO3a. Low concentrations of β-hydroxybutyrate (1-2 mM) can lead to inhibition of
HDAC 1 increasing histone acetylation and leading to the increased expression of genes
downstream of the transcription factor FOXO3a (144). Protein products downstream of
FOXO3a, MnSOD and catalase, were elevated in kidney tissue isolated from βhydroxybutyrate treated rats (144). It therefore appears that β-hydroxybutyrate can reduce
oxidative stress by increasing histone acetylation near genes downstream of FOXO3a,
allowing for this transcription factor to bind to its now available promoter leading to the
transcription and translation of MnSOD and catalase. Another gene regulated by
FOXO3a, metallothionein 2, was also upregulated and may contribute to reductions in
oxidative stress through metal ion sequestration (Fe, Cu) and quenching of free radicals
such as superoxide and the hydroxyl radical (138). In comparison, individuals with MetS,
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show increased oxidative stress, decreased antioxidant status and increased urinary 8-epiPGF2α (47, 52, 152, 166, 169).

The reduction in ROS generation is not the only mechanism for decreased lipid
peroxidation. Small, dense LDL (sdLDL) are increased in individuals with MetS (79).
SdLDL are more susceptible to peroxidation than larger, more dense LDL (31, 163). This
seems to be due to a greater quantity of PUFA in the sdLDL and a lower amount of free
cholesterol (31, 163). PUFA are the most readily peroxidizable lipids and free cholesterol
seems to protect lipids from oxidation potentially by decreasing the permeability of the
phospholipid monolayer to superoxide (163). LCDs have been shown to change the LDL
particle distribution toward the less atherogenic pattern A by increasing mean LDL
particle size (38, 89, 174). A LCD therefore leads to lower lipid peroxidation by
increasing LDL particle size, decreasing the susceptibility of the LDL to peroxidation,
and decreasing ROS generation.

Summary
Hypocaloric LCD improve metabolic parameters to a greater degree than a LFD. These
improvements include, body mass, body composition, blood lipids and inflammation.
Hypocaloric LCD also show consistent changes in blood lipid composition such as
increased ARA and decreased SFA and palmitoleic acid. The increase in ARA is
facilitated by a decrease in oxidative stress with consumption of a LCD. Overall, LCD
have greater metabolic and health benefits on the risk factors associated with MetS than a
comparative LFD.

Insulin Resistance

Insulin Signaling Pathway
The insulin receptor is a heterotetramer consisting of two ligand binding alpha subunits
on the external membrane surface and two beta subunits inside the plasma membrane
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which have tyrosine kinase activity (172). The insulin signaling cascade initiates with the
binding of insulin to the alpha subunit of the insulin receptor. This leads to induction of
the tyrosine kinase capabilities of the beta subunits leading to autophosphorylation. The
insulin receptor substrate (IRS) temporarily binds to the insulin receptor leading to
phosphorylation of several of its tyrosine residues. Once phosphorylated the IRS can now
be bound by SH2 domain containing proteins (172). Phosphoinositide3-kinase (PI3K)
consists of two subunits, the p85α regulatory subunit with an SH2 domain and the
p110 subunit with catalytic activity. PI3K binds to the IRS docking protein through
its p85α subunit which leads to the activation of the p110 subunit. The p110 subunit
then converts the plasma membrane lipid phosphoinositol 4,5-bisphosphate (PIP2)
to phosphoinositol 3,4,5-trisphosphate (PIP3). Akt/PKB (protein kinase B) contains
a PH domain (pleckstrin homology) which binds the newly created PIP3 anchoring it
to the plasma membrane (112, 172). The now anchored PKB can be activated by
PDK1 (phosphoinositide-dependent protein kinase-1) which also co-localizes to
PIP3 by its own PH domain and mTORC2 (mammalian target of rapamycin complex
2) on threonine-308 and serine 473 respectively (112). PKB then acts on several
small GTPases which induce the translocation of GLUT4 containing vesicles and
SNARE regulatory proteins which mediate GLUT4 vesicle fusion to the plasma
membrane (94).

Perturbations in Insulin Signaling
Modifications to proteins in the insulin signaling cascade have been a focus of research
into the mechanisms of insulin resistance. These modifications are diverse, ranging from
transcriptional regulation to post-translational modifications resulting in altered
functionality or decreased protein content. Many parts of the insulin signaling cascade are
affected from the insulin receptor to GLUT4.

Initiation of the insulin signaling cascade begins with the insulin receptor itself (insulin is
the effector of this pathway). Studies of leukocytes from obese individuals stratified
based on the level of obesity indicate increasing pathologies with increased obesity.
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Individuals with a BMI under 40 show decreased numbers of both total and high-affinity
insulin receptors but with a compensatory increase in receptor affinity and insulin
secretion, allowing for the maintenance of insulin binding (12). Obese individuals with a
BMI above 40 show decreased numbers of both total and high-affinity insulin receptors
with a concomitant decrease in insulin receptor affinity and insulin secretion (12). These
studies indicate a reduction in insulin receptor protein content associated with the level of
obesity.

Plasma cell differentiation factor-1 (PC-1) is an inhibitor of tyrosine kinase activity
(101). Fibroblasts from diabetic individuals have increased PC-1 protein expression and
overexpression in cell culture decreases the tyrosine kinase activity of the insulin receptor
(101). In non-obese, non-diabetic individuals, PC-1 content in both skeletal muscle and
adipose tissue is negatively correlated with insulin sensitivity as assessed by the
intravenous insulin tolerance test (50, 51). PC-1 also has a soluble form (sPC-1) in the
plasma with similar molecular weight and enzyme activity to tissue bound PC-1 (Frittita
1999). sPC-1 is inversely related to skeletal muscle PC-1 content and its concentration in
plasma negatively correlates with the waist/hip ratio and mean blood pressure (Frittitta
1999). These studies indicate that PC-1 mediated inhibition of insulin receptor tyrosine
kinase activity may play a role in insulin resistance in both skeletal muscle and adipose
tissue.

There are over 50 serine/threonine residues on IRS-1 and IRS-2 (28). Phosphorylation of
these residues leads to either reduced tyrosine phosphorylation of the IRS by the insulin
receptor or to degradation of the IRS, both leading to decreased insulin mediated action
(58, 123). The reduction in insulin receptor induced tyrosine phosphorylation of IRS is
caused by reduced binding of IRS to the juxtamembrane region of the insulin receptor,
thereby reducing the association of IRS with the insulin receptor resulting in reduced
tyrosine phosphorylation of IRS (123). The specific residue that is phosphorylated
dictates the fate of the IRS protein, with different serine kinases having varying affinities
for each residue (58, 97, 100, 168). Many serine residues can be phosphorylated at one
time, thereby affording intricate regulation to the activity of the IRS (100, 168).
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Further downstream of the insulin receptor lies glucose transporter 4 (GLUT4), which is
responsible for insulin mediated glucose uptake. GLUT4 receptor density is greater on
slow twitch (ST) muscle fibers than fast twitch (FT) muscle fibers in lean healthy
subjects (55). Compared to lean control counterparts, obese and obese individuals with
T2DM demonstrated decreased GLUT4 protein expression in ST muscle fibers of 20%
and 40% respectively (55). Other studies found no difference in GLUT4 expression of
skeletal muscle from obese or insulin resistant individuals because they homogenized the
muscle tissue prior to analysis instead of analyzing in tact cells by fiber type (54, 124)
Obese individuals with T2DM have lower GLUT4 protein density in ST fibers than FT
fibers in contrast to lean and obese non-insulin resistant counterparts (55). In addition,
obesity and insulin resistance alter the ST/FT ratio (55). These modifications in GLUT4
expression likely explain the dichotomy observed in studies that homogenize muscle
tissue.

Subcutaneous adipocytes from T2DM individuals have decreased IRS-1 protein
expression and unchanged IRS-2 protein expression, leading to an increased role for IRS2 as the substrate for tyrosine phosphorylation by the insulin receptor (136). However,
IRS-2 required a greater insulin concentration than IRS-1 to bind and stimulate PI3K
activity (136). Although serine phosphorylation of IRS-1 can lead to degradation of IRS1 (58), modification of IRS-1 gene expression may also modulate IRS-1 protein levels.
Adipose tissue from non-obese, non-diabetic subjects showed decreased IRS-1 protein
expression predominantly in subjects with a family history of T2DM, but was present in
subjects without any genetic pre-determinants as well (20). Subjects with low IRS-1
protein expression, reduced by 65% in comparison to controls, had significantly greater
adipocyte cell size and a waist/hip ratio indicative of increased abdominal fat. These low
IRS-1 individuals also had low GLUT4 protein expression and low mRNA expression of
both IRS-1 (~50%) and GLUT4 (~60%) (20).

Decrements in IRS-1 protein and GLUT4 expression have been associated with obesity
as explained above and increased adipocyte cell size associated with obesity has been
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shown to increase circulating levels of the cytokine TNF-α (63). Exposure of 3T3-L1
adipocytes to TNF-α for 96h showed decreased protein expression of both IRS-1 and
GLUT4 by 80% with minimal decreases to insulin receptor protein expression
(155). However, the remaining protein content functions normally. The insulin
receptor still autophosphorylated and GLUT4 still translocated from intracellular
vesicles to the plasma membrane indicating that multiple simultaneous
modifications to the insulin signaling pathway likely occur to result in the insulin
resistant phenotype observed at the organismal level (155).

There are a multitude of proteins modified in the insulin signaling cascade with reduced
insulin sensitivity all the way to insulin resistance. The interactions of these many protein
modifications lead to a diverse set of mechanisms behind insulin resistance. However,
regardless of the complexity of these modifications, perturbations to insulin signaling are
not restricted to protein modifications. There is evidence that cellular lipids also play an
important role in the regulation of insulin sensitivity.

The most commonly studied impact of cellular lipids on insulin resistance is through
intracellular lipid accumulation (5, 7, 15, 16, 30, 110, 114, 151, 158, 162, 167, 178).
Several studies indicate that intramyocellular lipids (IMCL) are elevated in obese, obese
diabetic and diabetic individuals often without decrements in mitochondrial oxidative
capacity (5, 7, 15, 16, 30, 110, 151, 158, 162, 178). However, it is not the accumulation
of intracellular lipids that is of the utmost importance but the location of these lipids.
Endurance trained athletes demonstrate increased IMCL but not insulin resistance (167).
In fact endurance trained athletes show greater concentrations of intracellular lipids than
overweight and overweight diabetic individuals (167). The major difference between
normal healthy sedentary and endurance trained individuals and individuals with diabetes
is the location of the IMCL (114). Endurance trained and healthy individuals show
greater lipid accumulation around the intermyofibrillar mitochondria while diabetic
individuals demonstrate greater localization of intracellular lipids around the
subsarcolemmal mitochondria (114). However in T2DM or obese individuals, endurance
training shifts the intracellular lipid localization from the subsarolemmal mitochondria to
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the intermyofibrillar mitochondria, and this transition is associated with an improvement
in insulin sensitivity (diabetics only) regardless of a lack of change in total IMCL (33,
114). Therefore the localization of intracellular lipid accumulation is more important than
the increase in intracellular lipids itself.

There is evidence of an emerging relationship between the lipid composition of the
plasma membrane and insulin resistance. In skeletal muscle insulin sensitivity is
positively associated with long chain PUFA (C20-22) (13, 121). Further investigation
demonstrates that ARA has the strongest positive relationship to insulin sensitivity as
assessed by euglycemic clamp of all the long chain PUFA and concomitantly the
strongest inverse relationship with fasting insulin (13, 121). In contrast, DGLA, a
precursor to ARA, has the strongest positive correlation to fasting insulin and the third
strongest negative correlation to insulin sensitivity of all the fatty acids including
palmitate, except palmitoleate and oleate (13, 121). The ARA/DGLA ratio had the
overall greatest negative correlation to fasting insulin and the overall greatest positive
correlation to insulin sensitivity, greater than that of ARA alone and of the percentage of
total long chain PUFA (13). ARA also shows the strongest inverse relationships to
percent body fat and BMI of any fatty acid while DGLA shows the strongest direct
relationship of any fatty acid (121). The relationship of ARA to insulin sensitivity is best
explained by the role of ARA in the organization of the plasma membrane.

Plasma Membrane Organization

Development of a Membrane Organization Model
In 1972 Singer and Nicholson proposed their model system for membranes which
consisted of a fluid mosaic of alternating proteins and phospholipids which were
seemingly unorganized (150). The concept of lipids being organized into domains with a
functional impact was proposed not long after in 1982 (85). Lipid rafts were initially
proposed in 1997 as lipid domains consisting of sphingolipids and cholesterol as the base
of a lipid platform used to promote cell signaling (147). Nine years later in 2006 lipid
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rafts were renamed to membrane rafts and officially defined as “small (10–200 nm),
heterogeneous, highly dynamic, sterol and sphingolipid-enriched domains that
compartmentalize cellular processes. Small rafts can sometimes be stabilized to form
larger platforms through protein-protein and protein-lipid interactions” (134).

Formation of Lipid Rafts
The formation of lipid rafts is due to lipid-lipid, lipid-protein and protein-protein
interactions. Lipid-lipid interactions focus on the relationships between sphingolipids,
cholesterol and other lipids. Sphingolipids have special properties which aid in both
microdomain formation and tight packing with cholesterol. The sphingosine headgroup
of sphingolipids contains an 18 carbon amino alcohol with a single unsaturation just
beneath the head group (149). Sphingolipids contain only a single fatty acid moiety
which is usually a saturated fatty acid with 16-24 carbons. The lack of unsaturated carbon
bonds allows cholesterol to pack closely to spingolipids. The amide linkage in
spingolipids may, although not finitely proven, bind to the 3-OH group of cholesterol
enforcing their proximity. Finally, the sphingosine back bone contains an amido and
hydroxyl group which both allow for the formation of hydrogen bonds either with water
or other lipids, including other spingolipids (148). The hydrogen bond forming potential
not only allows for the bonding to various lipids but also to lateral stability allowing for
domain formation. The interaction of cholesterol with other hydrocarbon chains forces
them into elongated conformations, leading to thicker membrane regions which may
promote segregation based on hydrophobic mismatch (98). The combined properties of
sphingolipids and cholesterol lead to the formation of thick, dense and ordered domains
(98, 148).

Lipid-protein interactions also play an important role in raft formation. Proteins inserted
in the membranes have individual structures and as such are fitted to specific lipids (98).
These lipids are often referred to as non-annular lipids and cannot be separated from the
protein via detergent extraction (98). The acyl chains of these lipids fill in the grooves of
the proteins (70). The specific lipid is determined in part by the protein length or the
length of its transmembrane domain if it has one (98). Earlier it was mentioned that lipid
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raft domains are dense and thick and so the thickness or length of a protein-lipid
assembly may play a part in its allocation to a raft or non-raft fraction. Many membrane
proteins also have sphingolipid binding domains which could facilitate their
incorporation into lipid rafts (98). Protein-protein interactions facilitate the fusion of
smaller lipid raft domains into larger signaling complexes (98). Smaller rafts can contain
a signaling protein. When the signaling protein binds its ligand, a multimer can form. The
formation of a multimer creates a cross-link between the proteins of two lipid rafts,
facilitating coalescence of the lipid rafts.

Lipid Raft Composition
Lipid rafts are bilayer structures (span both the exofacial and cytofacial leaflets of the
plasma membrane)(132). In comparison to the bulk plasma membrane, lipid rafts contain
twice as much cholesterol, 30% more sphingomyelin, 3-4x increase in PS, decreased PI
and PC, the same PE content and are enriched in PE plasmalogen species containing
arachidonic acid (132). The greater concentration of PE plasmalogens in rafts leads to a
30% greater concentration of arachidonic acid in the raft fraction than the bulk membrane
(132). Lipid rafts can be isolated by detergent or non-detergent methods. When rafts are
isolated with cold 1% Triton X-100 mixed in a buffer, homogenized and isolated by
flotation on a 5% to 30% linear sucrose density gradient, they are called detergent
resistant membranes or DRMs(18). However, the use of different detergents such as NP40, CHAPS, Brij 98, octylglucoside and Lubrol yield rafts with slightly different lipid
compositions (39, 81, 137). Lipid rafts can also be isolated via non-detergent methods
such as isotonic sucrose or mechanical lysis, followed by density gradient separation to
yield plasma membrane only lipid rafts that closely resemble those found in the live cell
(153). The difference in lipid composition between DRMs and lipid rafts is that the
detergent method tends to selectively extract the exofacial leaflet lipids and exclude the
cytofacial leaflet lipids. This makes the DRMs appear to have a greater concentration of
saturated lipids and lower levels of glycerophospholipids such as anionic phospholipids,
phosphatidylethanolamine and PE plasmalogens (132). This is because the cytofacial
leaflet contains the anionic phospholipids as well as PE while the exofacial leaflet
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contains cholesterol, sphingomyelin and glycosphingolipids (such as the gangliosides
GM1,-2 and -3) (29, 42, 125, 133).

Lipid Rafts and Insulin Signaling
Tyrosine kinases are frequently found in lipid rafts (133). One tyrosine kinase, the
insulin receptor, is constitutively located in caveolae in cells that have caveolae (165). In
cells that lack caveolae, insulin receptors are recruited into rafts by insulin (165).
Receptors that are constitutively located in or are recruited into lipid rafts are dependent
on lipid raft integrity (133). Tyrosine phosphorylation occurs primarily in lipid rafts
(99). Cholesterol depletion studies which disrupt lipid raft integrity have shown no
change in the ability of insulin to bind to the insulin receptor (122), but show decreases
in several downstream events such as IRS-1 phosphorylation (122, 165), activation of
PKB/Akt (122), ATP citrate lyase phosphorylation (64), glucose uptake (64, 122) and
glucose oxidation (92). There may or may not be a decrease in autophosphorylation of
the tyrosine kinase (122, 165). (Cholesterol depletion is carried out using methyl-βcyclodextrin, filipin or lovastatin.) Also within the tyrosine kinase cascade, at least half
of the PIP3 precursor PIP2 is located within lipid rafts (72, 131). 1-stearoyl 2-aracidonoyl
is the major molecular species of the phosphoinositides (25, 69, 71, 74). The importance
of arachidonic acid to phosphoinositides may be that it provides a specific substrate for
phosphoinisitide modifying proteins including phosphoinositide kinases and
phosphatases. It has been shown that phosphoinositide phosphatases show substrate
specificity based on the head group and the fatty acid composition of the
polyphosphoinositide (139). Also given the diverse actions of the various PI3K IA class,
they may have substrate specificity as well. Although phosphatidylinositol, the precursor
to the phosphoinositides is more resistant to loss of arachidonic acid than other
phospholipids (66, 175), it is possible that decreases in membrane phosphatidylinositol
ARA content, could affect the generation of molecular species of phosphoinositides,
changing the preferences of its kinases and phosphatases, leading to modified insulin
signaling.
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Overall Summary

High carbohydrate diets promote insulin resistance, with evidence of the onset of insulin
resistance prior to weight gain and inflammation. In an attempt to dispose of the excess
CHO consumed, de novo lipogenesis converts glucose carbons to free fatty acids altering
the pool of circulating triglycerides by favoring the addition of palmitate, oleate and
palmitoleate, potentially modifying other circulating fatty acids in hepatically-derived
lipid fractions. Excessive carbohydrate intake also promotes increased inflammation and
oxidative stress, potentially altering fatty acid composition through reactive oxygen
species-mediated destruction of highly unsaturated fatty acids. This leads to an altered
circulating lipid composition, modifying the lipid environment of the cells. The
phospholipid and fatty acid composition of the membrane is important, with different
fatty acids having varying effects on insulin sensitivity. Arachidonic acid not only has the
greatest positive relationship to insulin sensitivity, but it is highest in concentration in
lipid rafts, the plasma membrane site of insulin signaling. In contrast, the arachidonic
acid precursor, dihomo-gamma linolenic acid (DGLA), shows one of the strongest
negative relationships to insulin sensitivity. Therefore manipulation of dietary
carbohydrate may modify the circulating lipid composition which may in turn alter
insulin sensitivity by affecting membrane fatty acid composition. Low carbohydrate diets
have emerged as an effective counter measure to MetS improving the circulating lipid
profile, decreasing inflammation, decreasing body mass and improving insulin
sensitivity. However, the mechanism(s) by which a low carbohydrate diet induce
alterations in insulin sensitivity have not yet been identified. Therefore the purpose of this
project is to determine how manipulating the carbohydrate and fat content of the diet
affects circulating serum lipids, and how this might alter the plasma membrane
composition of cells affecting insulin sensitivity in individuals with metabolic syndrome.
In order to accomplish this goal, cheek cells will be used as a cellular model system to
study the effects of the diet on membrane fatty acid composition and individuals with
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MetS will be enrolled since individuals with this disorder are known to possess varying
levels of insulin resistance.
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Chapter 3: Methods

Study Participants
Individuals with metabolic syndrome were recruited as participants in this study.
Potential subjects were screened for participation based on the criteria for metabolic
syndrome which was defined as having three or more of the following: waist
circumference (≥101.6 cm men, ≥88.9 cm women), blood pressure (≥130/85 mm Hg) or
current use of antihypertensive medication, and fasting plasma glucose (≥100 mg/dL),
triglycerides (≥150 mg/dL), and HDL-C (<40 mg/dL men, <50 mg/dL women). During
the screening process subjects were excluded if they were diagnosed with Type I or II
Diabetes, liver, kidney, or other metabolic or endocrine dysfunction or if they were trying
to lose weight or had a body mass change of ±3 kg in the previous 3 months. Fifteen
overweight/obese men and women aged 30-66 were enrolled. Their characteristics are
summarized in Table 1.1. The participants in this study were primarily sedentary,
however those who were physically active were asked to maintain their current training
regime (verified by activity logs) while the sedentary individuals were instructed not to
engage in a new exercise regimen to limit the effects of physical activity on the
dependent variables. The study was approved by the University of Connecticut
Institutional Review Board and all participants signed an informed consent form.

Dietary Intervention
Baseline dietary information was obtained via 3-day food record logs and analyzed using
nutrient analysis software. The menu/diet composition for each of the six feeding phases
ranging in carbohydrate content from 47g to 346g/dy was generated using the same
nutrient analysis software (Nutritionist Pro, Axxya Systems, Stafford, Texas). The total
calories consumed during each diet phase were individualized based on the baseline
resting metabolic cart data and an activity factor (1.2-1.5). Calories were reduced by 300
kcal/d from the determined needs of each subject to allow for gradual weight loss as a
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motivation for participation in the ~5 month study. Saturated fat, monounsaturated fat
and polyunsaturated fat were kept at 46%, 34% and 20% of total fat content respectively
for every phase. Protein was maintained at 1.8 g/kg reference body weight according to
the Metropolitan Height-Weight tables. Therefore total calories and protein content were
maintained throughout each phase while the total calories derived from fat and
carbohydrate were modified.

Dietary Analysis
Since the nutrient analysis software does not contain lipid data for the arachidonic acid
content of foods the USDA National Nutrient Database for Standard Reference Release
26 was consulted. However, even this database only provides 20:4 undifferentiated
polyunsaturated fatty acid content (20:4n3 and 20:4n6). Food descriptions in the nutrition
software were matched as closely as possible to the USDA database to ascertain the
content of undifferentiated 20-carbon polyunsaturated fatty acids (20:4UD). The specific
arachidonic acid content of whole eggs, one of the primary dietary sources of ARA, was
ascertained from an article assessing the accuracy of the lipid content of some commonly
consumed foods in comparison to the USDA database (159). This article demonstrated a
60% increase in arachidonic acid content of whole cooked eggs in comparison to the
USDA database. The arachidonic acid content of cooked wild Alaskan native sockeye
salmon was not listed in the USDA database, so the uncooked value of this fish was used
in the ARA calculations. There are plans to have cooked samples of this fish analyzed for
lipid composition at a later date. Other animal sources of arachidonic acid could not be
compared between the USDA database and the literature given the specificity,
preparation and number of food items.

The total amount (in grams) of food items by category in the following categories were
tallied: beef, egg, dairy, fish, poultry and pork. Vegetables and nuts were excluded from
the analyses as they contain little to no arachidonic acid content. The tallied gram
amounts for each food item in each category were used in combination with the 24UD
values for the specific food items to determine the total 24UD content for each food
category and the total overall 24UD intake for each week in phases I and VI of the diet
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intervention study. 24UD consumption per week instead of per phase was determined
since participation in each diet phase was not of uniform duration due to scheduling,
illnesses or other unforeseen and uncontrollable circumstances. The duration of phase I
and phase VI averaged 4.75 and 3.2 weeks respectively.
Fat Mass
Body composition was assessed by dual energy x-ray absorptiometry (DEXA) (Lunar
Prodigy, GE Healthcare, Pittsburgh, PA) at the end of each diet phase in the morning
after an overnight fast.
Blood andBuccal Cell Collection and Processing
Subjects arrived at the Human Performance Laboratory after a minimum 12hr fast (with
the exception of water) and 24hr abstinence from exercise, caffeine, over the counter
medications and alcohol. Subjects provided a urine sample prior to blood collection for
the assessment of hydration status by urine specific gravity. An acceptable USG was
under 1.025 and subjects above this cutoff were provided with water followed by a
second USG assessment after a 30 min waiting period.
Blood samples were obtained from a vein in the antecubital fossa or lower arm after
subjects sat in a reclined position for 15 min. Whole blood was collected into EDTA,
serum and serum separator vacuum tubes using a butterfly needle. Plasma tubes were
immediately spun in a benchtop centrifuge chilled to 4oC at 1500 xg for 15 min. Serum
tubes were allowed to clot for 15 min at room temperature prior to centrifugation with the
same settings as plasma samples. The serum separator tube was sent to a certified
medical laboratory (Quest Diagnostics, Wallingford, CT) for assessment of glucose, total
cholesterol (TC), HDL-C, TG, and calculated LDL-C concentrations using automated
enzymatic procedures (Olympus America Inc., Melville, NY). The plasma and serum
samples were aliquoted into cryostorage tubes and stored in an ultra-low freezer for batch
analysis.
Subjects were provided with a cup of water and instructed to rinse their mouths for 15
seconds. Subjects were then provided two stiff bristle brushes (MasterAmp Buccal Swab
Brush, Epicentre Biotechnologies, Madison WI). The subjects were instructed to rub the
bush vigorously against the interior of the cheeks, one brush per cheek, while rotating the
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brush head. The brush heads were then detached from the stems and placed in a screw
cap cryostorage tube with 1 mL of water. The buccal samples were then stored in an
ultra-low temperature freezer for batch analysis.

Analysis of Insulin
Insulin was assayed in duplicate using an ELISA kit (ALPCO, Salem NH). Intra- and
inter-assay coefficients of variation (CV) were 5.3 and 7.2% respectively.

Analysis of Insulin Sensitivity
Insulin sensitivity was evaluated by the homeostasis model assessment 2 (HOMA2) (95).
HOMA is an index model derived from fasting blood glucose and insulin concentrations
(103). Both the insulin resistance (HOMA-IR) and insulin sensitivity (HOMA%S)
indices were used and calculated using the downloadable excel sheet with built in macros
(164).

Plasma and Buccal Cell Fatty Acid Analysis
Plasma and buccal cell lipids were analyzed as previously described by Lipid
Technologies LLC (Austin, MN USA)(49). In summary the procedure used for the
analysis was as follows. Lipids were extracted from samples by the method of BlighDryer whereby samples were mixed with chloroform, methanol and water causing
partitioning of lipids into the resulting chloroform layer (11). Lipid extracts were dried
under a stream of nitrogen gas and resuspended in 50 μL of chloroform. Lipid classes
including but not limited to triglycerides, phospholipids and cholesterol esters were
separated on commercial silica gel G plates (AnalTech, Newark, DE, USA). The
chromatographic plates were developed in a solvent system consisting of petroleum ether
(bp 30-60oC).:diethyl ether:acetic acid (80:20:1, by volume). Subsequent to development,
the silica gel plates were sprayed with a methanolic solution containing 0.5% 2,7dichlorofluorescein which was then used to visualize the lipid classes under ultraviolet
light. The lipid bands of interest were then scraped into Teflon lined screw cap tubes. The
samples were then transesterified using 10% boron trifluoride in methanol (Supelco,
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Bellefonte, PA, USA) in an 80oC water bath for 90 min. Resulting fatty acid methyl
esters were extracted with water and petroleum ether and stored frozen until analysis by
gas chromatography.

The fatty acid methyl ester composition of the lipid classes was analyzed by capillary gas
chromatography. Methyl ester samples were dried under nitrogen gas and resuspended in
hexane. The fatty acid methyl esters were separated and quantified using a Shimadzu
capillary gas chromatograph (GC 17) using a 30 m Restek free fatty acid phase (FFAP)
coating and EZChrom software. The instrument temperature was programmed from 190
to 240oC at 7oC/min with a final hold of 10 min resulting in the separation and
measurement of fatty acid methyl esters ranging from 12:0 to 24:1. The detector
temperature was 250oC. Helium was used as a carrier gas at a flow rate of 1.4 mL/min
and a split ratio of 1:25. Chromatographic data was collected and analyzed by EZChrom
software (Scientific Products, CA, USA). Fatty acids were identified by comparison to
fatty acid standards and quantitating using peak area in comparison to internal standards.
Resolution of individual peaks was distinguishable for peaks representing 0.05% of the
total fatty acid methyl esters. Plasma fatty acid data is presented in relative terms (wt%).

Statistical Analysis
Dietary Intake. Normality testing was performed using the Kolmogorov-Smirnov test.
The Wilcoxon signed rank test was performed on the dietary intake data. The alpha level
was set at p ≤ 0.05. Exact significance values were used for comparison to the alpha
level.
Plasma Fatty Acid Analysis. Normal data was analyzed using the Student’s paired Ttest while non-normal data was analyzed using both the paired Student’s T-test and the
Wilcoxon signed rank test. Two-tailed Exact significance values were generated for the
Wilcoxon signed rank test. Since the parametric and nonparametric analyses were in
agreement, all statistical values were reported from the parametric tests. The alpha level
was set at p ≤ 0.05.
Buccal Cell Lipid Composition, Insulin Sensitivity And Fat Mass Loss. Data was
analyzed using the paired Student’s T-test for buccal cell fatty acids, HOMA2-IR and fat
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mass loss. The Wilcoxon signed rank test was used to assess HOMA2%S as the data was
not normal. The alpha level was set at p ≤ 0.05.
Correlations. Pearson correlations were used to assess the relationships between insulin
sensitivity scores and plasma and buccal cell fatty acids both within each diet phase and
as the change between each phase. The alpha level was set at p ≤ 0.05.
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Chapter 4: Results

Subject Characteristics
A total of 15 participants were enrolled in this study consisting of 11 men and 4 women.
The average age of the participants was 45.1 ± 10.2. Waist circumference and blood
pressure were the two most frequently occurring MetS qualifying characteristics present
in 87 and 73% of participants respectively. Five subjects were taking medication to treat
high blood pressure. The average BMI was 37.8 ± 6.4 kg/m2. All participants were
considered obese based on BMI except for one participant who was overweight. A
complete list of subject characteristics is listed in Table 1.1.

Dietary Analysis
The greatest amount of arachidonic acid was consumed during phase I at 2.69 g/wk in
comparison to phase VI at 1.27 g/wk. This led to a daily decrease in arachidonic acid
intake of 204 mg/dy during phase VI in comparison to phase I. During phase I
significantly more fatty meats and whole eggs were consumed while during phase VI
significantly more low-fat dairy was consumed. During phase I significantly greater
amounts of arachidonic acid were consumed from beef, dairy, egg and pork. In phase I
the greatest amount of arachidonate was derived from eggs (~56%) and pork (~15%),
while during phase VI the greatest amount of arachidonate was derived from eggs
(~38%) and poultry (~25%) (Figure 1.1 to 1.4). The sharp decline in total pork
consumption between the diet phases led to the decrease in arachidonic acid derived from
pork. Eggs were the greatest source of arachidonic acid in the diet during both phases
with 239 mg/100g of ARA in egg. Although more dairy was consumed during phase VI,
the substitution of reduced fat dairy products, mainly American cheese, cream cheese and
the removal of sour cream, the only arachidonic acid containing dairy products, led to a
greater amount of arachidonic acid derived from dairy during phase I. A complete
nutrient analysis is provided in Table 1.2.
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Fat Mass
Total fat mass loss during phase I was greater than during phase VI (-2.22 ±1.49 kg vs 0.28 ± 1.53 kg, P = 0.000). Fat mass loss per week was also significantly greater during
phase I than phase VI (-0.47 ± 0.31 kg vs -0.09 ± 0.48 kg, P = 0.001).

Plasma Lipids
Triglycerides. In the triglyceride omega-6 fraction 18:3n6, 20:2n6, 20:3n6 and 22:4n6
increased from phase I to phase VI while arachidonic acid (20:4n6) itself decreased (see
Table 2.1). Of the remaining fatty acids in the triglyceride fraction 16:1n7 and 20:1n9
increased while 14:1n5, 18:1n9, 20:3n9, 18:2n6, 22:5n6 and all the measured n-3 PUFA
18:3n3, 20:5n3, 22:5n3 and 22:6n3 did not differ between phases.
Cholesterol Esters. In the cholesterol ester fraction 20:4n6 and its initial precursor,
18:2n6, decreased while desaturation and elongation intermediates in the arachidonic acid
pathway 18:3n6 and 20:3n6 increased between phases I and VI (see Table 2.2). Of the n3 PUFA 18:3n3 increased while its elongation and desaturation products 20:5n3 and
22:6n3 did not change. The MUFA 16:1n7 increased and 18:1n9 was unchanged.
Phospholipids. In the phospholipid fraction the omega-6 fatty acids changed as follows
from phase I to phase VI: 18:2n6, 18:3n6 and 22:5n6 did not change, 20:2n6 and 20:3n6
increased while 20:4n6 and 22:4n6 decreased (see Table 2.3). The omega-3 fatty acids
20:5n3 and 22:6n3 did not change while 22:5n3 increased. Palmitoleic acid (16:1n7) did
not change nor did any of the omega-9 fatty acids 20:1n9, 20:3n9, 22:1n9 and 24:1n9
with the exception of oleic acid, which tended to increase from phase I to phase VI (P =
0.097).

Plasma Fatty Acids and Insulin Sensitivity
HOMA2 Scores. The HOMA2-IR score increased from phase I to phase VI (1.20 ± 0.44
to 1.46 ± 0.62, P = 0.05) indicating an increase in insulin resistance. However the change
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in insulin sensitivity (HOMA2%S) was not significant (99.62 ± 14.66 to 83.97 ± 12.35, P
= 0.249).
HOMA2-IR Phase I. HOMA2-IR in phase I was correlated to the following fatty acids
during phase I (see Table 3.1): TG16:1n7 and PL20:3n9 tended to be positively
correlated (P = 0.056 and P = 0.098), PL24:1n9 tended to be negatively correlated,
CE16:1n7 and the linoleic acid products PL 20:2n6 and 20:3n6 were significantly
positively correlated while PL22:1n9 and ARA (20:4n6) in all 3 lipoprotein subfractions
was significantly negatively correlated.
Insulin Sensitivity (HOMA2%S) Phase I. HOMA2%S in phase I was correlated to the
following fatty acids during phase I (see Table 3.1): PL20:4n6 and PL24:1n9 tended to be
positively correlated (P = 0.095 and P = 0.051), CE18:3n6, PL20:2n6, PL22:5n6 tended
to be negatively correlated (P = 0.052, P = 0.066 and P = 0.81 respectively), TG20:4n6
and PL22:1n9 were significantly positively correlated while TG16:1n7, CE16:1n7 and
PL20:3n6 were significantly negatively correlated. The differences between the measures
of insulin resistance and insulin sensitivity were: CE 18:3n6 was a new tendency in
HOMA%S only, PL20:2n6 and PL20:4n6 only tended in HOMA%S and CE20:4n6 and
PL20:3n9 were not correlated to HOMA2%S. It is uncertain why these differences exist
since HOMA2-IR is simply the inverse of HOMA2%S.
HOMA2-IR Phase VI. HOMA2-IR in phase VI was correlated to the following fatty
acids during phase VI (see Table 3.1): TG22:4n6, CE20:4n6 and PL20:4n6 tended to be
negatively correlated (P = 0.057, P = 0.067 and P = 0.095 respectively),TG20:4n6,
TG20:5n3 and TG22:6n3 were significantly negatively correlated.
Insulin Sensitivity (HOMA2%S) Phase VI. HOMA2%S in phase VI was correlated to
the following fatty acids during phase VI (see Table 3.1): TG22:4n6, TG20:5n3 and
TG22:6n3 tended to be positively correlated (P = 0.053, P = 0.081 and P = 0.083
respectively), PL20:1n9 and ARA (20:4n6) in all three lipoprotein subfractions were
significantly positively correlated. The differences between HOMA2-IR and HOMA2%S
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were as follows: CE 20:4n6 became significantly correlated instead of a tendency, TG
and PL 20:4n6 were newly significantly related and TG 20:5n3 and TG 22:6n3 were no
longer correlated with HOMA2%S.
Overall. Arachidonic acid in all three fractions was related to measures of insulin
sensitivity, indicating that it was positively associated with insulin sensitivity. No other
fatty acids had a consistent association with measures of insulin sensitivity in both
phases.

Buccal Cell Fatty Acids
In cheek cell total lipids the omega-6 PUFA DGLA (20:3n6) increased while ARA
(20:4n6) decreased from phase I to phase VI. Of the omega-3 PUFA, α-linolenic acid
(18:3n3) and EPA (20:5n3) both increased. Of the MUFA palmitoleic acid (16:1n7)
increased, while oleic acid (18:1n9) and nervonic acid (24:1n9) decreased from phase I to
phase VI. A summary of all the changes in buccal cell fatty acids is provided in Table
2.4.

Buccal Cell Fatty Acids and Insulin Sensitivity
HOMA2-IR in phase I was significantly positively correlated to 20:3n6 and 22:1n9,
significantly negatively correlated to 24:1n9 and the ARA:DGLA ratio and tended to be
significantly negatively correlated to 18:1n9. HOMA2%S in phase I tended to be
positively correlated 14:1n5, 18:1n9, and 24:0, tended to be negatively correlated to
16:1n7 and 22:1n9 and was significantly positively correlated to 24:1n9 and the
ARA:DGLA ratio. HOMA2%S in phase VI tended to be positively correlated to 14:1n5
and 22:6n3 and was significantly positively correlated to 20:2n6. A summary of all the
meaningful correlations between measures of insulin sensitivity and buccal cell fatty
acids is presented in Table 3.2.
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Correlations of the Changes Between Phases for All Lipids and Measures of Insulin
Sensitivity
The change in HOMA2-IR between phases I and VI tended to be positively correlated to
the change in buccal cell 22:4n6, phospholipid 18:2n6 and 22:1n9, tended to be
negatively correlated to buccal cell 22:1n9 and phospholipid 22:6n3 and was significantly
negatively correlated to phospholipid 22:5n3. The change in HOMA2%S between phases
I and VI tended to be positively correlated to the change in buccal cell 24:0 and
phospholipid 20:4n6, tended to be negatively correlated to buccal cell 20:5n3 and
phospholipid 22:1n9 and was significantly negatively correlated to buccal cell 22:4n6 and
cholesteryl ester 22:6n3. There were no significant correlations between the changes in
HOMA scores and the changes in plasma triglyceride fatty acids. A summary of all the
correlations between the changes in HOMA scores and all lipids can be found in Table
3.3.
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Chapter 5: Discussion

Dietary Intake
Total arachidonic acid intake during phase I was 2.69 g/wk (385 mg/d) while during
phase VI it was 1.27 g/wk (181 mg/d). This amounted to a weekly difference of 1.42
g/wk or 204 mg/d less arachidonic acid consumption during phase VI. During phase I
arachidonic acid was primarily derived from egg followed by pork, poultry, beef, fish and
dairy. The combined contribution of pork, poultry, beef, fish and dairy consumption to
the total arachidonic acid consumed was less than the contribution of egg. During phase
VI arachidonic acid was again primarily derived from egg, followed by poultry, beef,
fish, pork and dairy. However, during phase VI, the amount of arachidonic acid derived
from egg did not exceed the total amount of arachidonic acid consumed from all the other
food sources combined. The amount of arachidonic acid from egg decreased dramatically
by about 1.012 g/wk or 68%. The total amount of arachidonic acid consumed from fish
and poultry did not change between phases. Although the amount of arachidonic acid
intake from beef, dairy and pork decreased during phase VI, their contribution to the
difference in arachidonic acid consumed between phases was negligible in comparison to
the loss from decreased egg consumption. The reduction in egg consumption was
primarily driven by the replacement of eggs for breakfast by carbohydrate rich foods such
as waffles, cereals and oatmeal and dairy products such as yogurt.

Plasma Fatty Acids
ARA was greater and DGLA was lower in all 3 lipoprotein fractions in phase I in
comparison to phase VI. These inverse changes between ARA and its immediate
precursor, DGLA, agree with the findings of previous low carbohydrate diet studies (49,
129). ARA supplementation studies also find increased ARA in all 3 lipoprotein
fractions, but DGLA did not significantly decrease in any fraction. Instead linoleic acid
decreased in the CE and PL fractions while oleate and linoleic acid both non-significantly
declined in the TG fraction (84, 113). This is an important distinction between the results
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in this study and our prior work (49, 129) where circulating DGLA significantly and
consistently decreased across all subjects consuming a very low-carbohydrate diet, and
the results of ARA supplementation studies where DGLA is not altered (84, 113). In
low carbohydrate diets the changes in 5acid in the three fractions vary, likely depending
on the different diets employed in the studies (49, 129). In this study linoleic acid
decreased in the CE fraction but did not change in either the TG or PL fractions.
Therefore a disparity exists between increased ARA intake as either a supplement or as
part of the food in the diet. When ARA is increased through selected food consumption,
the increase in ARA is paralleled by a decrease in DGLA, but when ARA is increased
through supplementation it inhibits incorporation of linoleic acid into all the lipoprotein
subfractions. The difference in linoleic acid incorporation into lipoproteins between ARA
supplementation and low carbohydrate diet studies may be due to differences in linoleic
acid intake. Supplementation with ARA capsules only increases the consumption of
ARA, but whole foods can provide ARA as well as other fatty acids, such as linoleic
acid. Eggs for example are not only a good source of ARA but also of the essential fatty
acid linoleic acid. An alternative explanation for the decrease in linoleic acid with
supplementation of high levels of ARA is competitive absorption. Linoleic acid
absorption has been shown to be decreased when competing with higher levels of ARA
and α-linolenic acid in rat intestines (23, 24, 135).

Augmentation of serum phospholipid ARA is consistently observed during low
carbohydrate diets. Although there are several potential mechanisms by which ARA is
increased on a low carbohydrate diet, the composition and caloric intake of the diet
affects the contribution of each mechanism. It has been previously postulated that the
increase in plasma ARA content with consumption of a low carbohydrate diet is
facilitated by a reduction in oxidative stress, leading to a decline in the peroxidation of
ARA and better preservation of the existing ARA pool (48). This controlled low
carbohydrate diet feeding study observed a decrease in urinary isoprostane PGF2α, a
peroxidation product of ARA after 6 weeks (48). Further evidence of decreased oxidative
stress during a LCD has ben observed in animal studies. In the hippocampal mitochondria
of rats fed a ketogenic diet, observations of increased glutathione, increased uncoupling
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protein expression and decreased hydrogen peroxide production have all been observed
(83, 157). Increased Nrf2 activation and its downstream products HO-1 and NQO1 have
also been observed in the livers of rats after 3 weeks on a ketogenic diet as well as a
decrease in mitochondrial hydrogen peroxide production (108). However, liver
concentrations of glutathione were decreased for the duration of the ketogenic diet (108).
In addition, 4-HNE, a lipid peroxidation product of linoleic and arachidonic acids, was
initially increased on the diet and although it decreased thereafter, it was still elevated to
a non-significant degree above the control diet group (108).

Ketogenic diets initially demonstrate increased oxidative stress (107, 108). However,
through activation of the Nrf2 pathway and ketone body induced effects on mitochondrial
superoxide dismutase, antioxidant defenses are augmented, leading to reduced oxidative
stress (107, 144). However, the time course of these adaptation has been speculated to be
about 3 weeks (107). But there is evidence that it may be a longer duration before these
adaptations take place. Rats fed a ketogenic diet for 4 weeks showed no difference in
liver 4-HNE in comparison to a standard chow diet, but they showed a dramatic increase
in 4-HNE catabolism indicating that HNE disposal was increased (96). In addition, liver
concentrations of ascorbic acid and the GSH/GSSR ratio were reduced in comparison to a
standard diet (96). However, despite the increase in lipid peroxidation and oxidative
stress, liver concentrations of linoleic acid and arachidonic acid were elevated in the
ketogenic diet group in comparison to the standard diet group (96). The increase in
linoleic acid is likely due to the nearly 3.5 fold increase in linoleic acid intake during the
ketogenic diet, but no group received any arachidonic acid in their diets. Therefore,
despite increased lipid peroxidation and no arachidonic acid in the diet, liver arachidonic
acid still increased on the ketogenic diet. Therefore it seems likely that after consumption
of a ketogenic diet for a greater duration than 3-4 weeks, the increase in antioxidant
capacity could facilitate a decrease in lipid peroxidation, augmenting the ARA pool, but
for shorter durations the adaptations may not be complete. In this study the controlled
feeding ketogenic diet was 3 weeks in duration, but it was preceded by 3 weeks of a freeliving ketogenic diet leading to a duration of 6 weeks on a ketogenic diet. So it is possible
by this point that the antioxidant adaptations to the low carbohydrate diet could have
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contributed to the increase in the ARA pool. However, since no measurements of lipid
peroxidation products or their catabolic metabolites have been assessed yet, it is uncertain
what the contribution of decreased oxidative stress would be.

A greater increase in dietary arachidonic acid intake may also contribute to the rise in
serum phospholipid ARA observed during low-carbohydrate diets. In this study, an
estimated additional 204 mg/d of ARA was consumed in phase I vs phase VI. Since this
is the first low carbohydrate diet study to control and quantitate dietary intake in both the
low carbohydrate and standard diet phases comparisons to previous low carbohydrate
literature are difficult, but a higher level of arachidonic acid intake in another controlled
low carbohydrate diet feeding study was also associated with an increase in serum PL
ARA (48). Supplementation with ARA capsules have also shown increased serum PL
ARA (84, 113). Further evidence to support the contribution of dietary ARA to the ARA
pool is observed in mice lacking delta-6-desturase and are therefore unable to
endogenously produce ARA from linoleic acid. These mice demonstrate very low levels
of tissue ARA in comparison to wild type littermates (156). However, supplementation of
their standard diet with arachidonic acid shows improvements to normal levels of ARA in
the tested tissue of brain and skin (156).

A third possible mechanism to explain the rise in circulating ARA is release from adipose
tissue. Adipose tissue triglycerides contain between 0.17 and 0.20 percent ARA (43,
119). Therefore the loss of fat mass or the overall greater flux of fatty acid cycling could
manifest in release of ARA into the serum PL ARA pool. Fat mass loss totaled 2.22 kg
and 0.28 kg during phases I and VI respectively. Hypothetically, that would have led to
the release of 5-fold greater amounts of ARA during phase I and VI respectively (i.e.,
approximately 123 mg/d and 23 mg/d, respectively).

Finally, changes in endogenous synthesis of ARA from its precursor linoleic acid,
derived from either dietary or adipose tissue stores, may have also contributed to the
observed differences in serum PL ARA, but differences in ARA synthesis were not
assessed in this study. However, the lack of change in serum PL mead acid, a product of
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oleic acid produced by the same pathway as ARA synthesis, did not significantly change
between phases, potentially indicating a lack of change in endogenous synthesis.

The phospholipid fraction of the lipoprotein particle may be the preferred site of ARA for
transport through the circulation for a couple of reasons. Normal rats injected with
radiolabeled ARA, linoleic and α-linolenic acids into the portal veins had their livers
excised (32). Analysis of the liver homogenate showed that the greatest amount of
radiolabel in the liver phospholipids was from ARA (32). Chylomicron remnants with
radiolabeled ARA incubated with HepG2 cells showed that ARA was predominantly
incorporated into phospholipids (22). Together these studies indicate that the liver
preferentially packs ingested ARA into phospholipids, potentially for repackaging into
lipoproteins. LDL modified with radiolabeled ARA prepackaged in phospholipids,
transfer their radiolableled ARA to platelets and erythrocytes which can be used for
eicosanoid production (37, 40, 80). Lastly, animal work demonstrating that radiolabeled
ARA fed to rats showed the greatest amount of radioactivity in the phospholipid fraction
of lymph lipids (27). These data demonstrate the preferential packaging of ingested lipids
in the liver into phospholipids and the transfer of these phospholipid concentrated with
ARA to cells and platelets through lipoproteins.

Many plasma fatty acids showed moderate to strong relationships with insulin resistance
in either phase I or phase VI, but the majority of fatty acids did not maintain these
relationships with insulin resistance between both phases. The majority of these fatty
acids were long chain polyunsaturated fats (greater than 20 carbons). The only fatty acid
that showed a consistent and strong relationship in both diet phases in the plasma was
ARA in the TG fraction, which was inversely correlated to insulin resistance. ARA in the
CE and PL pools were inversely related to insulin resistance during phase I, but were
reduced to tending toward significance in phase VI. Clupanodonic acid was the only
plasma fatty acid that correlated with the change in insulin resistance between diet
phases.
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In summary, the highly significant and consistent increase in circulating ARA after
feeding a low-carbohydrate diet could be a result of multiple factors including better
preservation of the existing ARA pool, increased dietary intake, and greater release into
the circulation from adipose triglyceride stores.

Buccal Cell Lipids
Analysis of total cellular lipids from buccal cells indicated that ARA was significantly
lower while DGLA was significantly greater during phase VI than phase I. These changes
in cellular lipids mirrored the changes in the plasma phospholipid fraction of the
lipoproteins. The buccal cell MUFA palmitoleic acid increased from phase I to VI while
oleic acid and nervonic acid decreased, potentially to balance the increase in palmitoleic
acid. The omega-3 fatty acids α-linolenic acid and EPA increased from phase I to phase
VI. These changes in MUFA and omega-3 PUFA were not observed in the plasma
phospholipid fraction of the lipoproteins. Although palmitoleic acid did increase in the
CE and TG fractions no changes were observed in oleic acid, or EPA and α-linolenic acid
decreased in the CE fraction in opposition to the increase observed in the buccal cells.
The similar response of plasma phospholipids by buccal cell lipids may be due to the
strong tendency for ARA to partition into phospholipids. Although buccal cell
palmitoleic acid did not mirror plasma phospholipids the increase in the CE and TG
fractions may have still contributed to its increase in the buccal cells since total cellular
lipids were analyzed. The changes in the other fatty acids could have been compensatory
changes to balance the total MUFA and PUFA of the cells. The majority of cellular lipids
are in the phospholipid fraction and in this fraction of cells there is a necessity to balance
the saturation:unsaturation index likely due to an attempt to maintain cellular membrane
fluidity which is important for the maintenance of cellular functions (6, 75, 117, 126,
142, 143).

There were no significant relationships between the change in buccal cell lipids and the
change in HOMA scores between phases I and VI that were consistent between the
measures of insulin sensitivity. There were also no consistent correlations between buccal
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cell lipids and measures of insulin sensitivity in both diet phases. DGLA showed a
significant positive relationship while the ARA:DGLA showed a significant negative
relationship to HOMA-IR during phase I. These correlations are consistent with
previously established relationships between muscle phospholipids and insulin sensitivity
as assessed by the hyperinsulinemic-euglycemic clamp (13, 121). However, the strong
positive correlation between insulin sensitivity and muscle phospholipid ARA was not
observed in the buccal cells. This could have potentially arisen from buccal cell total
lipids and not only the phospholipid fraction being assessed in this study. It may also be
related to the physiologically important role of muscle as a primary organ in the disposal
of plasma glucose. The heterogeneity of changes in both the HOMA scores and the
cellular lipids between subjects may have played a role. A fourth factor that could have
affected this relationship is the study population. The relationships between insulin
sensitivity and skeletal muscle fatty acids were performed in healthy, normally insulin
sensitive individuals while participants in this study had MetS. To the knowledge of this
author, no papers comparing the fatty acid composition of buccal cells or skeletal muscle
in healthy vs MetS individuals has been performed. Therefore it is unknown if the
relationships between fatty acids and insulin sensitivity would change. Another
significant difference is the use of the hyperinsulinemic-euglycemic clamp to assess
insulin sensitivity in comparison to the use of HOMA scores. Although HOMA scores
and the hyperinsulinemic-euglycemic clamp have a high degree of correlation for the
estimation of insulin resistance their means of assessing insulin resistance are still
different (direct vs indirect index) (176).

Limitations
The USDA database lists a value of 0.080 g/100g for the ARA content of raw native
Alaskan sockeye salmon which is likely to underestimate the cooked value. Therefore
incorporating this value into the total arachidonic acid intake calculation results in a
lower actual arachidonic acid intake. However, currently the USDA database does not list
a cooked value for this particular type of fish. There are plans to have the fatty acid
composition of the cooked fish assessed in the future. However, the corrected value for
salmon will not have a great effect on the total arachidonic acid intake and the large
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relative difference between the low-carbohydrate and high-carbohydrate diet phases since
salmon consumption did not differ between diet phases. Correlations between buccal cell
lipids and HOMA scores are also limited in comparison to previous studies utilizing
muscle phospholipids as total cellular lipids, not solely the phospholipid fraction was
assessed in this study.
Conclusion
In conclusion this study demonstrates that a low carbohydrate diet, in comparison to a
diet homologous to a standard Western diet, increases plasma and cellular ARA and
decreases the proportion of the ARA precursor DGLA in both fractions. This study also
demonstrates the significant positive relationship between plasma arachidonic acid and
insulin sensitivity. Although plasma arachidonate was correlated to insulin sensitivity,
buccal cell arachidonate was not which contrasts the findings observed in skeletal
muscle.

Further Research
In order to further explore the relationship between cellular lipid composition and insulin
sensitivity leukocytes were isolated from subjects following each diet. These leukocytes
were cryopreserved and analyzed for total cellular lipid composition. In addition, an
assay was developed using a fluorescent glucose analogue, 6-NBDG, in order to
determine differences in insulin mediated glucose uptake in leukocyte subset populations.
The purpose of this effort was to determine differences in insulin sensitivity at a cellular
level between the diet phases. The analysis of leukocyte lipids and the development of
the glucose analogue assay are discussed and the results provided in appendix II.
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Appendix I

Subjects Characteristics, MetS Qualifiers and Experimental Diet Analysis

Table 1.1: Baseline Characteristics of the Participants

Baseline Participant Characteristics
Characteristic
Value
45.13 ± 10.19
Age (yrs)
169.54 ± 9.42
Height (cm)
108.05 ± 15.83
Weight (kg)
37.81 ± 6.41
BMI (kg/m2)
111.37 ± 13.23
Waist (cm)
124.83 ± 8.98
Systolic BP (mm Hg)
81.51 ± 8.66
Diastolic BP (mm Hg)
189.13 ± 28.23
Total Cholesterol (mg/dL)
40.73 ± 8.34
HDL (mg/dL)
127.36 ± 37.98
LDL (mg/dL)
155.43 ± 97.46
TAG (mg/dL)
Glucose (mg/dL)
103.87 ± 17.01
Values are means ± SD

46

Table 1.2: Nutritional Analysis of the Experimental Diets

Nutrient
Phase I
Phase VI
Energy (kcal/d)
2533.09 ± 329.187
2486.54 ± 334.49
Protein (%)
20.50 ± 2.012
19.80 ± 1.70
Protein (g)
128.36 ± 6.814
122.10 ± 11.47
Carbohydrate (%)
7.44 ± 0.827
56.11 ± 5.13
Carbohydrate (g)
46.52 ± 1.865
345.58 ± 28.52
Fiber (g)
15.46 ± 0.675
34.69 ± 4.93
Fat (%)
73.37 ± 2.857
27.42 ± 5.71
Fat (g)
207.43 ± 33.935
77.52 ± 26.03
SFA (%)
29.53 ± 1.329
11.10 ± 2.66
SFA (g)
83.48 ± 13.736
31.48 ± 11.39
MUFA (%)
26.80 ± 1.860
8.10 ± 1.83
MUFA (g)
75.96 ± 14.115
22.95 ± 8.04
Oleate (g)
70.60 ± 13.410
20.09 ± 7.33
PUFA (%)
11.96 ± 0.879
5.17 ± 1.29
PUFA (g)
33.62 ± 4.654
14.66 ± 5.54
n-3 PUFA (%)
1.22 ± 0.204
0.58 ± 0.14
n-6 PUFA (%)
10.74 ± 0.711
4.59 ± 1.17
18:2n6 (g)
26.42 ± 4.085
10.56 ± 4.30
18:3n3 (g)
2.92 ± 0.625
1.23 ± 0.51
20:4n6 (g)
2.69 ± 0.320
1.27 ± 0.57
20:5n3 (g)
0.16 ± 0.073
0.12 ± 0.04
22:6n3 (g)
0.33 ± 0.116
0.28 ± 0.07
Values are mean percentages ± SD. Diets were analyzed using Nutritionist
Pro, Axxya Systems, Stafford, Texas
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Lipid Values for Plasma Lipoprotein Fractions and Buccal Cells
Table 2.1: Plasma Triglyceride Fatty Acids in Phase I and Phase VI

Plasma Triglycerides
Fatty Acid Name
Myristoleic acid
Palmitoleic acid
Oleic acid
Eicosenoic acid
Mead acid
Linoleic acid
γ-Linolenic acid
Eicosadienoic acid
Dihomo-γ-Linolenic acid (DGLA)
Arachidonic acid (ARA)
Adrenic acid
Osbond acid
α-Linolenic acid
Eicosapentaenoic acid (EPA)
Clupanodonic acid
Docosahexaenoic acid (DHA)
Values are means ± SD
Units: wt %

Structure
(14:1n5)
(16:1n7)
(18:1n9)
(20:1n9)
(20:3n9)
(18:2n6)
(18:3n6)
(20:2n6)
(20:3n6)
(20:4n6)
(22:4n6)
(22:5n6)
(18:3n3)
(20:5n3)
(22:5n3)
(22:6n3)

Phase I
0.25 ± 0.52
2.63 ± 0.58
37.00 ± 2.77
0.23 ± 0.08
0.10 ± 0.01
21.39 ± 3.07
0.43 ± 0.13
0.22 ± 0.09
0.25 ± 0.10
1.77 ± 0.46
0.18 ± 0.04
0.47 ± 0.36
1.05 ± 0.47
0.20 ± 0.08
0.32 ± 0.12
0.73 ± 0.17
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Phase VI
0.17 ± 0.16
3.67 ± 0.94
35.57 ± 2.48
0.29 ± 0.06
0.08 ± 0.04
21.09 ± 3.95
0.55 ± 0.12
0.30 ± 0.09
0.43 ± 0.08
1.46 ± 0.34
0.20 ± 0.04
0.41 ± 0.29
1.15 ± 0.36
0.22 ± 0.07
0.33 ± 0.10
0.65 ± 0.27

p-value
0.601
0.000
0.147
0.004
0.249
0.755
0.024
0.005
0.000
0.002
0.028
0.605
0.339
0.364
0.889
0.378

Table 2.2: Plasma Cholesteryl Ester Fatty Acids in Phase I and Phase VI

Plasma Cholesteryl Esters
Fatty Acid Name
Palmitoleic acid
Oleic acid
Linoleic acid
γ-Linolenic acid
Dihomo-γ-Linolenic acid (DGLA)
Arachidonic acid (ARA)
α-Linolenic acid
Eicosapentaenoic acid (EPA)
Docosahexaenoic acid (DHA)
Values are means ± SD
Units: wt %

Structure
(16:1n7)
(18:1n9)
(18:2n6)
(18:3n6)
(20:3n6)
(20:4n6)
(18:3n3)
(20:5n3)
(22:6n3)

Phase I
1.69 ± 0.58
16.03 ± 1.55
54.87 ± 4.47
0.48 ± 0.21
0.53 ± 0.22
9.04 ± 1.35
0.33 ± 0.08
0.59 ± 0.22
0.49 ± 0.09

Phase VI
2.59 ± 0.85
16.07 ± 1.24
52.68 ± 4.27
0.95 ± 0.37
0.92 ± 0.23
7.13 ± 1.19
0.51 ± 0.13
0.67 ± 0.16
0.52 ± 0.25

p-value
0.000
0.928
0.010
0.000
0.000
0.000
0.000
0.232
0.609

Table 2.3: Plasma Phospholipid Fatty Acids in Phase I and Phase VI

Plasma Phospholipids
Fatty Acid Name
Palmitoleic acid
Oleic acid
Eicosenoic acid
Mead acid
Erucic acid
Nervonic acid
Linoleic acid
γ-Linolenic acid
Eicosadienoic acid
Dihomo-γ-Linolenic acid (DGLA)
Arachidonic acid (ARA)
Adrenic acid
Osbond acid
Eicosapentaenoic acid (EPA)
Clupanodonic acid
Docosahexaenoic acid (DHA)
Values are means ± SD
Units: wt %

Structure
(16:1n7)
(18:1n9)
(20:1n9)
(20:3n9)
(22:1n9)
(24:1n9)
(18:2n6)
(18:3n6)
(20:2n6)
(20:3n6)
(20:4n6)
(22:4n6)
(22:5n6)
(20:5n3)
(22:5n3)
(22:6n3)

Phase I
0.62 ± 0.32
8.25 ± 0.60
0.15 0.04
0.12 ± 0.05
0.52 ± 0.61
1.26 ± 0.38
21.05 ± 2.02
0.14 ± 0.09
0.27 ± 0.10
2.26 ± 0.79
13.24 ± 1.73
0.36 ± 0.08
0.30 ± 0.09
0.69 ± 0.26
0.69 ± 0.15
3.16 ± 0.52
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Phase VI
0.69 ± 0.20
8.68 ± 0.77
0.16 0.04
0.15 ± 0.05
0.42 ± 0.55
1.24 ± 0.36
21.05 ± 2.57
0.13 ± 0.05
0.40 ± 0.11
3.61 ± 0.89
10.88 ± 1.46
0.41 ± 0.08
0.31 ± 0.16
0.67 ± 0.14
0.82 ± 0.17
3.08 ± 0.65

p-value
0.311
0.097
0.375
0.108
0.205
0.713
0.989
0.857
0.003
0.000
0.000
0.027
0.876
0.734
0.001
0.506

Table 2.4: Buccal Cell Fatty Acids in Phase I and Phase VI

Buccal Cell
Fatty Acid Name
Myristic acid
Myristoleic acid
Pentadecylic acid
Palmitic acid
Palmitoleic acid
Margaric acid
Heptadecanoleic acid
Stearic acid
Oleic acid
Linoleic acid
γ-Linolenic acid
α-Linolenic acid
Arachidic acid
Eicosadienoic acid
Dihomo-γ-Linolenic acid (DGLA)
Arachidonic acid (ARA)
Eicosapentaenoic acid (EPA)
Behenic acid
Eruric acid
Adrenic acid
Docosahexaenoic acid (DHA)
Lignoceric acid
Nervonic acid
Values are means ± SD
Units: wt %

Structure
(14:0)
(14:1n5)
(15:0)
(16:0)
(16:1n7)
(17:0)
(17:1)
(18:0)
(18:1n9)
(18:2n6)
(18:3n6)
(18:3n3)
(20:0)
(20:2n6)
(20:3n6)
(20:4n6)
(20:5n3)
(22:0)
(22:1n9)
(22:4n6)
(22:6n3)
(24:0)
(24:1n9)

Phase I
1.47 ± 0.39
0.53 ± 0.19
0.44 ± 0.10
14.40 ± 1.04
5.87 ± 1.30
1.03 ± 0.11
1.22 ± 0.46
13.18 ± 0.95
29.86 ± 2.99
17.65 ± 1.95
0.23 ± 0.17
0.17 ± 0.07
0.67 ± 0.12
0.24 ± 0.05
0.91 ± 0.25
3.66 ± 0.72
0.19 ± 0.15
1.02 ± 0.18
0.70 ± 0.48
0.44 ± 0.20
0.72 ± 0.25
1.95 ± 0.22
0.79 ± 0.92
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Phase VI
1.55 ± 0.96
0.63 ± 0.26
0.40 ± 0.14
14.69 ± 1.80
6.63 ± 0.95
0.98 ± 0.14
1.36 ± 0.42
13.11 ± 1.03
27.91 ± 1.99
17.36 ± 2.24
0.18 ± 0.07
0.25 ± 0.11
0.68 ± 0.12
0.25 ± 0.04
1.24 ± 0.29
2.95 ± 0.61
0.38 ± 0.40
1.00 ± 0.10
0.99 ± 0.86
0.52 ± 0.42
0.69 ± 0.21
2.19 ± 0.40
0.32 ± 0.31

p-value
0.698
0.230
0.150
0.485
0.014
0.149
0.092
0.829
0.015
0.589
0.291
0.033
0.880
0.227
0.000
0.000
0.034
0.760
0.185
0.438
0.531
0.139
0.031

Correlations Between Lipids and Indicators of Insulin Sensitivity

Table 3.1: Correlations Between Plasma Lipids and HOMA Scores
Correlations Between Plasma Fatty Acids and Indices of Insulin Sensitivity
Phase I
Phase VI
Fatty Acid
HOMA2-IR
HOMA2%S
HOMA2-IR
HOMA2%S
TG16:1n7
0.542 
-0.607 *
TG20:4n6
-0.674 *
0.688 **
-0.664 *
0.757 **
TG22:4n6
-0.540 
0.546 
TG20:5n3
-0.685 **
0.501 
TG22:6n3
-0.622 *
0.498 
CE16:1n7
0.617 *
-0.634 *
CE18:3n6
-0.549 
CE20:4n6
-0.567 *
-0.522 
0.606 *
PL20:1n9
0.608 *
PL20:3n9
0.524 
PL22:1n9
-0.719 **
0.788 **
PL24:1n9
-0.485 
0.551 
PL20:2n6
0.634 *
-0.524 
PL20:3n6
0.650 *
-0.636 *
PL20:4n6
-0.615 *
0.483 
-0.482 
0.618 *
PL22:5n6
-0.502 
TG: Triglyceride
* indicates p ≤ 0.05
CE: Choleteryl Ester
** indicates p ≤ 0.01
PL: Phospholipid
 indicates 0.05 < p ≤ 0.1
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Table 3.2: Correlations Between Buccal Cell Lipids and HOMA Scores

Correlations Between Buccal Cell Fatty Acids and Indices of Insulin Sensitivity
Phase I
Phase VI
HOMA2-IR
HOMA2%S
HOMA2-IR
HOMA2%S
Fatty Acid
14:1n5
0.517 
0.569 
16:1n7
-0.506 
18:1n9
-0.54 
0.504 
20:2n6
0.631 *
20:3n6
0.582 *
-0.564 *
22:1n9
0.574 *
-0.55 
22:6n3
0.545 
24:0
0.563 
24:1n9
-0.626 *
0.679 *
ARA:DGLA
-0.612 *
0.688 **
* indicates p ≤ 0.05
** indicates p ≤ 0.01
 indicates 0.05 < p ≤ 0.1
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Table 3.3: Correlations Between the Change Values of HOMA Scores and the Fatty
Acids of All Lipid Fractions
Correlations Between Changes in HOMA
Scores and Fatty Acids of Different Lipid
Fractions
HOMA2-IR HOMA2%S
BC20:5n3
-0.48 
BC22:1n9
-0.496 
BC22:4n6
0.476 
-0.898**
BC24:0
0.621 
CE22:6n3
-0.852**
PL18:2n6
0.525 
PL20:4n6
0.538 
PL22:5n3
-0.653 *
PL22:6n3
-0.494 
PL22:1n9
0.506 
-0.557 
* indicates p ≤ 0.05
BC: Buccal Cell Fatty Acids
** indicates p ≤ 0.001
CE: Cholesteryl Ester Fatty Acids
 indicates 0.05 < p ≤ 0.1 PL: Phospholipid Fatty Acids

53

The Contribution of Food Sources to Total Arachidonic Acid Consumption

Figure 1.1: Average Arachidonic Acid Intake (%) Phase I
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Figure 1.3: Average Arachidonic Acid Intake (%) Phase VI
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Supplemental Graphical Representation of Plasma and Cellular Lipids

Figure 2.1: Plasma Triglyceride Fatty Acids
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Figure 2.2: Plasma Cholesterol Ester Fatty Acids
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Figure 2.3: Plasma Phospholipid Fatty Acids
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Figure 3.1: The Relationship Between TG ARA and HOMA-IR During Phase I
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Appendix II
Isolation and Cryopreservation of Leukocytes
Total leukocytes were isolated from 20-30 mL of whole blood collected in EDTA tubes
using the red blood cell lysis technique. Samples were processed within 3 hours of
collection. Briefly, a 1x concentration of BD PharmLyse (Becton Dickinson Biosciences,
San Jose, CA) is added to an aliquot of blood in a 1:10 blood:lysis buffer ratio. Samples
are vortexed for 12 seconds followed by a 15 minute standing period to allow for lysis of
erythrocytes. Samples are then centrifuged at 200 rcf for 10 minutes to pellet the
leukocytes. The supernatant is removed and the pellet is resuspended in PBS-FBS (10%
FBS v/v) in a 1:8 blood:wash buffer ratio which is centrifuged at 200 rcf for 10 minutes.
The supernatant is removed followed by resuspension of the pellet in a total of 16 mL of
RPMI. A 50 µL sample is taken from the final cell suspension mixed in a 1:1 ratio with
trypan blue then diluted with a volume of RPMI sufficient to determine cell viability and
count under a brightfield microscope using a hemocytometer under a 40x objective
(128). After the cell count is obtained the cell suspension is centrifuged at 200 rcf for 10
minutes prior to the addition of cyromedia (70% RPMI v/v, 20% FBS v/v and 10%
DMSO v/v). Enough cyromedia was added to dilute the cells to 5x106 cells/mL. Cell
suspensions were kept in 2 mL screw cap cryogenic vials and brought down to -80oC at a
rate of 1oC/minute using Biocision Cool Cell chambers. The next day (at least 6-8 hrs
after placement in the deep freezer) cryovials were transferred to a liquid nitrogen freezer
for long term preservation.

Leukocyte Lipid Composition
The leukocytes were prepared for lipid extraction as follows. Cryovials of leukocytes
were thawed for 2 to 2.5 min in a 37oC. The 2 mL of thawed cells and cryomedia
suspension were added to a 50 mL polypropylene centrifuge tube containing 160 μL
DNAse I (10 mg/mL), 480 μL of autologous serum and 13.36 mL of PBS. The cell
suspension was incubated in the dark for 20 minutes at room temperature followed by
centrifugation at 200 rcf for 10 min at room temperature. The cells were then
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resuspended in PBS, transferred to a 13 x 100 borosilicate glass tube, centrifuged again at
the same settings followed by resuspension in 2 mL of 4:1 methanol:hexane plus 50
μg/mL BHT supplemented with 17:0 TG as an internal standard. Total leukocyte
lipids were then extracted by the method of Lepage and Roy (93). Briefly, the newly
suspended sample is vortexed, placed on an ice bath followed by the addition of 200 μL
of acetyl chloride. The tube is then sparged with nitrogen while incubated for 1hr in a
water bath at 100oC. The tube is then cooled in an ice bath, followed by the addition of
6% K2CO3, then centrifuged at 4000 rpm for 2 min. The upper hexane layer is then
removed for analysis. The methylated fatty acids solvated in hexane were analyzed by
gas chromatography (Shimadzu GC-2010 Plus) equipped with a flame ionization detector
and a DB-FFAP capillary column (15m x 0.1mm i.d. ,0.1 µm film thickness) (Agilent
Technologies). The temperature program was as follows: the initially set temperature was
150oC with a 0.25 min hold; ramp: 35C/min to 200C, 8C/min to 225C with a 3.2 min
hold, and then 80C/min to 245C with a 2.75 min hold. Fatty acid data are presented in
relative terms (weight percent).

6-NBDG Leukocyte Uptake Assay: Method Development
Flow cytometric analysis of the fluorescent glucose analogue, 6-NBDG (Life
Technologies, Carlsbad, CA), has not been previously performed in cryopreserved
leukocytes and therefore required method optimization. The initial factor assessed was
the type of media. RPMI (without glucose) (Life Technologies, Carlsbad, CA) and PBS
were compared, with RPMI strictly assessed in a 5% CO2 incubator kept at 37oC, while
PBS was tested in atmospheric conditions, at both room temperature and 37oC. PBS was
tested in the dark to simulate the light condition in the CO2 incubator. The scatter and
density plots of these media conditions were compared to that of freshly isolated cells. A
pre-incubation period was tested to determine if cells were more metabolically active,
determined by 6-NBDG uptake, immediately after thawing or given 2hr to acclimate
post-thaw. 6-NBDG uptake was tested at various concentrations from 0 to 40 μM. During
this testing propidium iodide was used to distinguish the uptake of 6-NBDG by live and
dead cells. It was discovered that dead cells took up quite a high proportion of 6-NBDG
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in comparison to live cells and so a dead cell removal kit was tested (Miltenyi Biotec,
San Diego, CA). Comparison of the results with and without the removal of dead cells
showed minimal alterations to the scatterplot, but it was observed that the dead and live
cells were proportionately removed, leading to an overall decrease in total cells. This was
likely due to the fact that the dead cell removal kit was suited for the removal of
apoptotic cells which can be removed by Annexin V. However, the dead cells present
under these testing conditions were likely necrotic cells which do no bear the Annexin V
ligand on their cell surface. Therefore testing was continued without removing the dead
cells. The plastic material for the incubation periods (pre-incubation and testing
conditions) was also tested. Tissue culture treated plastic was compared to
polypropylene. This was assessed using T-75 tissue culture treated flasks (BD
Biosciences, San Jose, CA) and 50 mL polypropylene centrifuge tubes (Fisher Scientific,
Pittsburgh, PA). In order to maximize cell viability and yield after thawing the presence
of 3% autologous serum and DNAse I (Roche Diagnostics, Indianapolis, IN) were tested
and the scatterplots compared. Initial staining with the leukocyte phenotypic surface
marker, CD3 (EMD Millipore, Temecula, CA), led to the discovery of extensive nonspecific binding. 4% methanol, 4% paraformaldehyde, 10 and 20% FBS (MP
Biomedicals, Santa Ana, CA) and 10 and 20% pooled human serum (not heat inactivated)
were compared for effectiveness. Insulin (Sigma-Aldrich, St. Louis, MO) concentrations
from 0 to 100 mIU/L were tested to determine which insulin concentration yielded the
greatest difference in 6-NBDG uptake from the basal (no insulin) condition. The
duration of incubation with insulin was also tested after an optimal insulin concentration
was determined. Finally the collection settings on the flow cytometer including flow rate,
the forward and side scatter thresholds and the number of events collected were assessed.

6-NBDG Leukocyte Uptake Assay: Method Development Results
Comparison of media types, RPMI and PBS, showed that PBS at room temperature
demonstrated the scatter plot and density plot closest to freshly isolated cells. It must be
noted that although the PBS condition was assessed immediately after the initial 2hr preincubation period, the RPMI condition was assessed after the insulin uptake assay. The

63

significance of this point is that the insulin uptake assay, at the time, was carried out
using tissue culture treated plastic, which affects the final scatter plot as will be described
below. The reason for this treatment difference was diminishing supplies of RPMI and
the fact that the PBS treated cell scatter plot closely resembled the freshly isolated cell
scatter plot. The use of PBS simplified the analysis process since a 5% CO2 incubator
was not required. An interesting observation was that both conditions carried out at 37oC
showed diminished concentrations of neutrophils and monocytes.
The material of the cell culture container for both the pre-incubation period and the
insulin uptake assay was assessed. Polystyrene tissue culture treated T-75 flasks were
compared against polypropylene 50 mL centrifuge tubes. The cells were pre-incubated in
RPMI for 2hr followed by the insulin uptake assay in tissue culture treated 12 well plates.
As can be seen, more cells clung to the tissue culture treated plastic than the
polypropylene container. Subsequent experiments were performed using only
polypropylene 50 mL conical tubes for the pre-incubation period and 12x75 mm
polypropylene culture tubes for the glucose uptake assay.
The metabolic activity of the cells post thaw was in question as this assay has not been
previously performed in frozen cells. Therefore the metabolic activity of the cells was
assessed immediately after thawing or after a pre-incubation period, allowing the cells to
sit in media undisturbed for 2hrs. Metabolic activity was assessed by quantifying the
mean fluorescence intensity (MFI) of concentrations of 6-NBDG from 10 to 40 μM in the
presence of 100 mIU/L of insulin for 1hr. This particular concentration of insulin was
chosen as it had been previously shown to induce maximal glucose analogue uptake in
leukocytes (35, 130). The MFI was always greater after a 2hr incubation period
indicating increased metabolic activity. However, as the concentration of NBDG was
increased, he difference in the MFI diminished, especially at 40 μM.
In order to determine the optimal concentration of 6-NBDG for the assay, cells were
incubated with concentrations of 6-NBDG ranging from 10 to 40 μM in the presence of
100 mIU/L of insulin. Propidium iodide was added to the cells just prior to reading on
the flow cytometer in order to distinguish the uptake of 6-NBDG by live and dead cells.
Uptake of 6-NBDG in live and dead cells showed the same pattern with increasing
concentrations of 6-NBDG, but the uptake by dead cells at each concentration exceeded
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that of live cells. Regardless, 30 μM was chosen as the optimal concentration as 40 μM
broke the trend in linearity of 6-NBDG uptake by the cells indicating that it was or was
close to a saturating concentration. An interesting observation here was that not only the
MFI of 6-NBDG uptake increased with increasing concentration, but so did the number
of live cells which internalized it.
After determining the optimal 6-NBDG concentration, insulin doses from 0 to 100 mIU/L
were assessed to determine the concentration of insulin that maximized the difference in
the MFI of NBDG uptake in comparison to the absence of insulin. This difference would
be defined as the insulin mediated uptake of glucose. This value was determined to be 60
mIU/L. The duration of incubation was tested and indicated that there was no difference
between 15 minutes and 60 minutes for 6-NBDG uptake under the optimal conditions.
This was expected based on previous studies using NBDG to assess insulin stimulated
glucose uptake in leukocytes (35). The initial use of the 1hr incubation period during
optimization of the NBDG and insulin concentrations was to ensure maximal uptake had
been achieved.
In order to maximize the number of viable cells the addition of 3% autologous serum was
tested as a media supplement. Autologous serum decreased the number of dead cells and
cell debris. Although it did not drastically alter the scatter plot, its effects can be observed
in the density plot. Autologous serum did improve cell viability, but cell yield was still
small. Clumps formed in the media after the 2hr pre-incubation period and in an attempt
to prevent the clumping of cells, DNAse was used to treat the cells during the 2hr preincubation period at a concentration of 0.1 mg/mL. DNAse treatment drastically
increased total cell yield and became a part of the pre-incubation media.
After having determined the cell culture containers , the composition of the preincubation media, and the optimal conditions for the glucose uptake assay, quantitation of
glucose uptake by cell type was first tested using the cell surface marker CD3, which
stains for T cells. The staining showed a great deal of non-specific binding. To find an
optimal blocking agent to prevent the non-specific binding of phenotypic antibodies 4%
methanol, 4% paraformaldehyde, 10 and 20% FBS and 10 and 20% human serum (not
heat inactivated) were compared. The best results were achieved using either 10 or 20%
FBS as no discernible difference between these two treatments were observed.
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Paraformaldehyde and methanol had no effect, in other words, fixation prior to staining
did not block non-specific binding. In addition, methanol was not a good candidate as it
fixes and permeabilizes cells, which may affect the planned quantitation of extracellular
GLUT4. Although human serum at both concentrations did also effectively prevent nonspecific binding, it reduced the total cell yield, removing it as a viable option.
All of these experiments were performed on cells taken from an individual who was not a
study participant. These cells were not cryopreserved as long as the subject samples. Test
samples were only frozen for two weeks up to two months in comparison to subject
samples that were frozen for close to two years. The realization that this assay would not
work in actual subject cells came after conditions were optimized and the assay was
tested on actual subject samples. The assay results did not replicate what was observed
using test subject cells. 6-NBDG uptake did not differ between the insulin and the noninsulin treatment conditions. Further testing on the test subject samples revealed that the
results of the assay varied with time frozen. Cells tested after 1 month of
cryopreservation had a response to insulin, but cells frozen for 2 months did not. Further
analysis of the insulin stimulated uptake of cells that had been frozen for 1 month or less
revealed that although the cells did respond to insulin it was not in the predicted pattern.
Although 60 mIU/L of insulin did elicit a response, it was not much greater than 30
mIU/L although it would be expected to be nearly double as observed in NBDG uptake
tested in freshly isolated lymphocytes when comparing 25 v 50 mIU/L of insulin (35).
Furthermore, cells tested only 1 day apart did not show the same insulin stimulated
NBDG uptake at the optimal concentration of 60 mIU/L. initialy it was thought that this
was due to a difference in the cocnetration of cells incubated in the assay. However, even
after manipulating the cell concentrations, the assay results were not replicable.
Therefore, even in newly frozen cells, insulin mediated glucose uptake is perturbed. This
indicated that cryopreserved cells have an abnormal response to insulin signaling.
Therefore, since all the cell samples had been cryopreserved, changes in insulin mediated
glucose uptake could not be observed.
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Table 4.1: Leukocyte Fatty Acid Composition

Leukocyte Lipids
Fatty Acid Name
Structure
Palmitic acid
(16:0)
Palmitic acid (DMA)
(16:0 DMA)
Palmitoleic acid
(16:1n7)
Stearic acid (DMA)
(18:0 DMA)
Stearic acid
(18:0)
Arachidic acid
(20:0)
Eicosadienoic acid
(20:2n6)
Behenic acid
(22:0)
Lignoceric acid
(24:0)
Oleic acid
(18:1n9 )
Gondoic acid
(20:1n9)
Eruric acid
(22:1n9)
Nervonic acid
(24:1n9)
Linoleic acid
(18:2n6)
Dihomo-γ-Linolenic acid (DGLA) (20:3n6)
Arachidonic acid (ARA)
(20:4n6)
Adrenic acid
(22:4n6)
Osbond acid
(22:5n6)
α-Linoleic acid
(18:3n3)
Eicosapentaenoic acid (EPA)
(20:5n3)
Clupanodonic acid
(22:5n3)
Docosahexaenoic acid (DHA)
(22:6n3)
Unknown
Values are means ± SD
Units: wt %

Phase I
21.92 ± 8.01
27.49 ± 10.06
0.13 ± 0.03
2.43 ± 0.58
9.88 ± 1.63
0.21 ± 0.05
0.31 ± 0.11
0.56 ± 0.16
0.75 ± 0.21
10.80 ± 2.44
0.29 ± 0.10
0.11 ± 0.04
1.97 ± 0.55
5.25 ± 3.59
0.70 ± 0.18
7.24 ± 1.50
1.32 ± 0.35
0.14 ± 0.07
0.07 ± 0.08
0.21 ± 0.05
0.73 ± 0.17
0.67 ± 0.23
6.70 ± 2.97
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Phase VI
21.99 ± 8.26
28.38 ± 15.25
0.12 ± 0.04
2.37 ± 0.98
10.03 ± 2.96
0.19 ± 0.07
0.35 ± 0.20
0.56 ± 0.23
0.84 ± 0.33
9.97 ± 3.86
0.22 ± 0.11
0.14 ± 0.09
1.99 ± 0.79
4.94 ± 2.10
0.97 ± 0.37
6.89 ± 2.62
1.22 ± 0.54
0.12 ± 0.06
0.04 ± 0.03
0.23 ± 0.12
0.84 ± 0.37
0.71 ± 0.29
6.83 ± 3.97

p-value
0.908
0.759
0.314
0.791
0.835
0.440
0.346
0.967
0.301
0.381

0.036
0.210
0.933
0.760

0.012
0.606
0.407
0.465
0.251
0.359
0.332
0.518

0.948
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